

10587989.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADK01625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	3	JAN 25	Annual Reload of MEDLINE database
NEWS	4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS	9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	11	APR 02	DWPI: New display format ALLSTR available
NEWS	12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	14	APR 07	CA/CAPLUS CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAPLUS
NEWS	16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

10587989.trn

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2010 HIGHEST RN 1221227-20-8

DICTIONARY FILE UPDATES: 3 MAY 2010 HIGHEST RN 1221227-20-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.





REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10587989-br2.str

10587989.trn



```
chain nodes :
18 19 21 22 29
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
ring/chain nodes :
20 23 26 27
chain bonds :
1-12 18-19 18-27 19-20 21-22 21-26 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
1-2 1-6 1-12 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 18-19 18-27 19-20 21-22
21-26 22-23
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17
```

G1:C,N

10587989.trn

G2:[*1],[*2]





Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 26:CLASS 27:CLASS 29:CLASS 30:Atom

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10587989-br1.str



chain nodes :

18 19 21 22 29

ring nodes :

1 2 3 4 5 6 7 8 9 12 13 14 15 16 17

ring/chain nodes :

20 23 26 27

chain bonds :

10587989.trn

1-12 18-19 18-27 19-20 21-22 21-26 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
1-2 1-6 1-12 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 18-19 18-27 19-20 21-22
21-26 22-23
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17

G1:C,N

G2:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 26:CLASS 27:CLASS 29:CLASS 30:Atom

L2 STRUCTURE UPLOADED

=> s 11
SAMPLE SEARCH INITIATED 15:18:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3798 TO ITERATE

52.7% PROCESSED 2000 ITERATIONS 36 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 72264 TO 79656
PROJECTED ANSWERS: 871 TO 1863

L3 36 SEA SSS SAM L1

=> s 12
SAMPLE SEARCH INITIATED 15:18:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3199 TO ITERATE

62.5% PROCESSED 2000 ITERATIONS 11 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 60588 TO 67372
PROJECTED ANSWERS: 100 TO 602

L4 11 SEA SSS SAM L2

=> s 11 or 12
SAMPLE SEARCH INITIATED 15:18:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5425 TO ITERATE

36.9% PROCESSED 2000 ITERATIONS 33 ANSWERS

10587989.trn

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 104083 TO 112917
PROJECTED ANSWERS: 1223 TO 2357

L5 33 SEA SSS SAM L1 OR L2

=> s l1 or l2 full
FULL SEARCH INITIATED 15:18:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 108268 TO ITERATE

100.0% PROCESSED 108268 ITERATIONS 1663 ANSWERS
SEARCH TIME: 00.00.05


L6 1663 SEA SSS FUL L1 OR L2

=> s l6 and C6N3/rf
 752055 C6N3/RF
L7 125 L6 AND C6N3/RF

=> d scan

10587989.trn


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-ethyl-3-[3-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-
methyl-
MF C22 H19 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):200

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-[3-[(1-methylethyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]-
MF C20 H23 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-(4-bromo-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C20 H14 Br F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-
pyrazolo[3,4-c]pyridin-5-yl]-
MF C23 H19 F N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-fluoro-5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)-
MF C25 H20 F2 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
MF C19 H13 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-[4-[3-amino-4-[4-(methylthio)phenyl]-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C32 H25 N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-ethyl-3-[3-(3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
4-methyl-
MF C23 H22 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-(1-acetyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-cyclopropyl-4-
methyl-
MF C19 H18 N4 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[3-[3-(4-bromophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C20 H15 Br N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[3-(3-thienylsulfonyl)-1H-
pyrazolo[3,4-c]pyridin-5-yl]-
MF C21 H17 F N4 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-[3-(acetylamino)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-
cyclopropyl-4-methyl-
MF C19 H19 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzoic acid,
4-[6-[4-(acetylamino)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
, ethyl ester
MF C23 H20 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(2-nitrophenyl)-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C31 H22 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
3-[3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-ethyl-4-
methyl-
MF C22 H19 Cl N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-cyclopropyl-3-fluoro-4-methyl-5-(1H-pyrazolo[3,4-c]pyridin-5-
yl)-
MF C17 H15 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-(2,4-dimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C22 H20 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-methylethyl)sulfonyl]-
1H-pyrazolo[3,4-c]pyridin-5-yl]-
MF C20 H21 F N4 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-[3-[(2-methyl-1-oxopropyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl]-
MF C21 H23 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(4-bromo-2-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C20 H14 Br F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-[4-(3-amino-4-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-
MF C25 H19 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide,
3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
N-ethyl-4-methyl-
MF C22 H18 Cl F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 3-Thiophenecarboxamide, N-[6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
MF C25 H16 F4 N6 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-3-fluoro-4-methyl-5-(1-phenyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-
MF C23 H19 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-1H-
pyrazolo[3,4-c]pyridin-5-yl]-
MF C24 H21 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-[3-[(1-oxopropyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]-
MF C20 H21 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C20 H14 Cl F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(3-phenyl-2-propen-1-yl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C28 H23 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-ethyl-3-[3-[(4-fluorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-
6-yl]-4-methyl-
MF C23 H21 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,
6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-
methyl-
MF C22 H16 F4 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-[1-(3-methylphenyl)-1H-pyrazolo[3,4-
c]pyridin-5-yl]-
MF C24 H22 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-6-oxido-
1H-pyrazolo[3,4-c]pyridin-5-yl]-
MF C24 H21 F N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-[3-[(4-methoxybenzoyl)amino]-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-
MF C25 H23 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(3,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C20 H14 Cl2 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(2-hydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C25 H19 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
3-[3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-
methyl-
MF C22 H19 Cl N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,
6-[3-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-
methyl-
MF C22 H16 F4 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxylic acid,
6-[4-(acetylamino)phenyl]-3-methyl-1-(tetrahydro-1,1-dioxido-3-thienyl)-,
methyl ester
MF C21 H22 N4 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-4-methyl-3-(6-oxido-1-phenyl-1H-pyrazolo[3,4-
c]pyridin-5-yl)-
MF C23 H20 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-4-methyl-3-[3-[(methylsulfonyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]-
MF C18 H19 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[4-[3-(4-bromophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C20 H15 Br N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-[4-(methylthio)phenyl]-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C26 H21 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-ethyl-3-[3-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-4-
methyl-
MF C22 H19 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C21 H18 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
3-[1-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-(2-
hydroxyethyl)-
MF C21 H16 Cl2 N4 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-ethyl-3-fluoro-5-[3-(4-methoxyphenyl)-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl-
MF C23 H21 F N4 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-[3-[(ethylsulfonyl)amino]-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-
MF C19 H21 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[4-[3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C21 H18 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(2-nitrophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C25 H18 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-ethyl-3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-
methyl-
MF C22 H19 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[3-[3-(4-Fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C20 H15 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(2-chlorophenyl)-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C31 H22 Cl N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-ethyl-3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl-
MF C22 H18 F2 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-[3-[(3-thienylsulfonyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]-
MF C21 H19 N5 O3 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C20 H14 Cl2 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-[1-[(1-methylethyl)sulfonyl]-1H-
pyrazolo[3,4-c]pyridin-5-yl]-
MF C20 H22 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide,
3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
4-methyl-N-(1-methyl-1H-pyrazol-5-yl)-
MF C24 H18 F2 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzoic acid,
4-[6-[3-(acetylamino)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
, ethyl ester
MF C23 H20 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-[4-[3-amino-4-(2-furanylmethyl)-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C30 H23 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide,
3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
N-ethyl-4-methyl-
MF C22 H18 Cl F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

```
L7 125 ANSWERS  REGISTRY  COPYRIGHT 2010 ACS on STN
IN  Benzanide, N-cyclopropyl-4-methyl-3-[3-[(2-thienylsulfonyl)amino]-1H-
MF  pyrazolo[3,4-b]pyridin-6-yl]-
C21 H19 N5 O3 S2
```




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-(3-(3,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl)phenyl]-
MF C20 H14 Cl2 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-
pyrazolo[3,4-c]pyridin-5-yl]-
MF C21 H17 F N4 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzamide,
3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
4-methyl-N-(1-methyl-1H-pyrazol-5-yl)-
MF C24 H18 F2 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzoic acid, 4-[6-[3-(aminocarbonyl)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester
MF C22 H18 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(4-hydroxy-3-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C32 H25 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-ethyl-4-methyl-
MF C23 H19 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-(3-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)-N-cyclopropyl-4-methyl-
MF C17 H15 Br N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[3-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C21 H15 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-
pyrazolo[3,4-c]pyridin-5-yl]-
MF C21 H17 F N4 O3 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)-N-cyclopropyl-4-
methyl-
MF C17 H17 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C21 H18 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C32 H25 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-ethyl-3-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-
MF C23 H21 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-(1H-pyrazolo[3,4-c]pyridin-5-yl)-
MF C17 H16 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[3-[3-(4-ethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C22 H20 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-
pyrazolo[3,4-c]pyridin-5-yl]-
MF C20 H21 F N4 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-[3-[(4-fluorobenzoyl)amino]-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-
MF C24 H20 F N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(4-bromo-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C20 H14 Br F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(3-phenoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C37 H27 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, 3-[[3-[(3,4-difluorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-methyl-
MF C23 H20 F2 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Urea,
N-[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)-
MF C20 H14 F4 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-[4-(4-methyl-1-piperazinyl)phenyl]-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C25 H26 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]-5-fluoro-4-methyl-
MF C20 H19 F N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, 3-[3-[(cyclopentylcarbonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-cyclopropyl-4-methyl-
MF C23 H25 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[4-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C20 H15 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-[4-[3-amino-4-(2-chlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C25 H18 Cl N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide,
3-[3-[(3-chlorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-methyl-
MF C23 H21 Cl N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,
6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-
MF C21 H14 F4 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-pyrazolo[3,4-
c]pyridin-5-yl]-
MF C19 H18 N4 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide,
N-cyclopropyl-4-methyl-3-(1-phenyl-1H-pyrazolo[3,4-c]pyridin-5-
yl)-
MF C23 H20 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-4-methyl-3-[3-[(4-methylbenzoyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]-
MF C25 H23 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide,
N-[4-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C21 H15 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(2-furanylmethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C24 H19 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-ethyl-3-[3-(3-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
4-methyl-
MF C23 H22 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,
6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-[2-(4-morpholinyl)ethyl]-
MF C27 H25 F4 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxylic acid,
6-[3-(acetylamino)phenyl]-3-methyl-1-(tetrahydro-1,1-dioxido-3-thienyl)-,
methyl ester
MF C21 H22 N4 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-cyclopropyl-3-[1-(2-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-
yl]-4-methyl-
MF C23 H19 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 2-Thiophenecarboxamide, N-[6-[5-[(cyclopropylamino)carbonyl]-2-
methylphenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
MF C22 H19 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C20 H14 Cl2 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-[4-[3-amino-4-(4-hydroxy-3-methoxyphenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C26 H21 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-ethyl-3-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl-
MF C23 H21 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,
6-[3-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-
[2-(4-morpholinyl)ethyl]-
MF C27 H25 F4 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-(2-cyanoethyl)-3-[1-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]-
MF C22 H15 Cl2 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-[1-(2-fluorophenyl)-6-oxido-1H-pyrazolo[3,4-
c]pyridin-5-yl]-4-methyl-
MF C23 H19 F N4 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-[3-[[4-(4-fluorophenyl)sulfonyl]amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]-4-methyl-
MF C23 H20 F N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C21 H17 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C26 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, 3-[3-(4-cyanophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-methyl-
MF C23 H19 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-(4-fluoro-3-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C21 H17 F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-[4-(3-amino-1,4-diphenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-
MF C31 H23 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-ethyl-3-fluoro-5-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl-
MF C23 H21 F N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-4-methyl-3-[(propylsulfonyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]-
MF C20 H23 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[4-[3-(2,4-dimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C22 H20 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-[4-[3-amino-4-(3-phenoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]-
MF C31 H23 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benamide, N-cyclopropyl-3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-
MF C23 H18 F2 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C20 H14 Cl F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-1-phenyl-4-(3-phenyl-2-propen-1-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C34 H27 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzoic acid, 4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester
MF C25 H24 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-[3-[[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl-
MF C22 H22 N6 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Acetamide, N-[3-[3-(4-bromo-2-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
MF C20 H14 Br F N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide,
N-cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-pyrazolo[3,4-
c]pyridin-5-yl]-
MF C21 H18 N4 O3 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, 3-fluoro-5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)-
MF C25 H20 F2 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzoic acid,
4-[6-[3-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-1H-
pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester
MF C26 H27 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10587989.trn

L7 125 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-[4-[3-amino-4-(2-hydroxyphenyl)-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]-
MF C31 H23 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10587989.trn

=> file caplus

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 May 2010 VOL 152 ISS 19
FILE LAST UPDATED: 3 May 2010 (20100503/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1	STRUCTURE UPLOADED
L2	STRUCTURE UPLOADED
L3	36 S L1
L4	11 S L2
L5	33 S L1 OR L2
L6	1663 S L1 OR L2 FULL
L7	125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

=> s 17

L8 7 L7

=> file reg

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

10587989.trn

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2010 HIGHEST RN 1221227-20-8
DICTIONARY FILE UPDATES: 3 MAY 2010 HIGHEST RN 1221227-20-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


```
=> tra rn l8
L9          TRANSFER L8 1- RN :      845 TERMS
L10         845 L9
```

```
=> s l7 not l10
L11         5 L7 NOT L10
```

```
=> d scan
```


10587989.trn


L11 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxylic acid,
6-[4-(acetylamino)phenyl]-3-methyl-1-(tetrahydro-1,1-dioxido-3-thienyl)-,
methyl ester
MF C21 H22 N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):11

L11 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-4-methyl-3-[1-(3-methylphenyl)-1H-pyrazolo[3,4-
c]pyridin-5-yl]-
MF C24 H22 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-(1-phenyl-1H-pyrazolo[3,4-
c]pyridin-5-yl)-
MF C23 H19 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L11 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-4-carboxylic acid,
6-[3-(acetylamino)phenyl]-3-methyl-1-(tetrahydro-1,1-dioxido-3-thienyl)-,
methyl ester
MF C21 H22 N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10587989.trn

L11 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Benzanide, N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-pyrazolo[3,4-
c]pyridin-5-yl]-
MF C19 H18 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10587989.trn

=> analyze l11

ENTER ANSWER NUMBER OR RANGE (1-):1-

ENTER DISPLAY CODE (CHEM) OR ?:so

'SO' IS NOT A VALID FIELD CODE FOR FILE 'REGISTRY'

The following are valid field codes:

AF ----- Alternate Molecular Formula

AR ----- Alternate Registry Number

CCI ----- Component Substance Class Identifier

CHEM ----- CAS Registry Numbers and Selected Names

CI ----- Substance Class Identifier

CMF ----- Component Molecular Formulas

CN ----- Chemical Names (Up to 50)

CRN ----- Component Registry Numbers

DEF ----- Definition

DR ----- Deleted Registry Number

EA ----- Elemental Analysis for Ring System

ES ----- Elemental Sequence for Ring System

FCN ----- All Chemical Names

FS ----- File Segment

IN ----- CA Index Name

LC ----- CAS Registry Number Locator

MF ----- Molecular Formula

NAME ----- Selected Substance Names

PCT ----- Polymer Class Term

PR ----- Preferred Registry Number

PN ----- Patent Number

RF ----- Ring System Formula

RID ----- Ring Identifier

RL----- CAplus Super roles

RLD ----- CAplus Super roles for non-specific Derivatives

RL.NP --- Roles from Non-patents

RL.P ---- Roles from Patents

RLD.NP -- Roles for non-specific derivatives from Non-patents

RLD.P --- Roles for non-specific derivatives from Patents

RLS ----- All CAplus Super roles

RLS.NP -- CAplus Super roles - Non-patents

RLS.P --- CAplus Super roles - Patents

RN ----- CAS Registry Number

RR ----- Replacing Registry Number

SCN ----- Short Chemical Name (IN and OTHER NAMES)

SEQ ----- Protein Sequence Display using 1 Letter Amino Acid Codes (default)

SEQ3 ----- Protein Sequence Display using 3 Letter Amino Acid Codes

SQEFPP --- Protein Sequence (exact family search form)

SQEN ----- Nucleic Acid Sequence (exact search form)

SQEP ----- Protein Sequence (exact search form)

SQSFP --- Protein Sequence (subsequence family search form)

SQSN ----- Nucleic Acid Sequence (subsequence search form)

SQSP ----- Protein Sequence (subsequence search form)

SR ----- Source of Registration

SZ ----- Size for Ring System

TAGS ----- Experimental Tags (same as ETAG)

ENTER DISPLAY CODE (CHEM) OR ?:sr

L12 ANALYZE L11 1- SR : 4 TERMS

=> d 112

10587989.trn

L12 ANALYZE L11 1- SR : 4 TERMS

TERM #	# OCC	# DOC	% DOC	SR
1	3	3	60.00	CHEMSPIDER (CHEMZOO, INC.)
2	3	3	60.00	OTHER SOURCES
3	2	2	40.00	CHEMICAL LIBRARY
4	2	2	40.00	LIFE CHEMICALS, INC.

***** END OF L12***

=> analyze l12

ENTER TERM RANGE (1-) OR ?:1-

L13 ANALYZE L12 1- : 4 TERMS

=> analyze l11

ENTER ANSWER NUMBER OR RANGE (1-):1-

ENTER DISPLAY CODE (CHEM) OR ?:ed

L14 ANALYZE L11 1- ED : 4 TERMS

=> d l14

L14 ANALYZE L11 1- ED : 4 TERMS

TERM #	# OCC	# DOC	% DOC	ED
1	2	2	40.00	13 AUG 2008
2	1	1	20.00	08 JUN 2008
3	1	1	20.00	10 JUN 2008
4	1	1	20.00	13 JUN 2008

***** END OF L14***

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED

L2 STRUCTURE UPLOADED

L3 36 S L1

L4 11 S L2

L5 33 S L1 OR L2

L6 1663 S L1 OR L2 FULL

L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

L10 845 SEA L9

10587989.trn

L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

=> file caplus

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 May 2010 VOL 152 ISS 19
FILE LAST UPDATED: 3 May 2010 (20100503/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

10587989.trn

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010
L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010
L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

=> s 16

L15 61 L6

=> s 115 and p38
23223 P38

L16 6 L15 AND P38

=> s 116 not 18

L17 5 L16 NOT L8

=> d 18 cbib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

10587989.trn

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2010 ACS ON STN
2009:1618457 Document No. 152:974930 Preparation of heterocyclylbenzamides, indanylbenzamides, and indanylpyridinecarboxamides as G protein-coupled receptor GPR52 agonists. Setoh, Masaki; Miyanoana, Yuhei; Kouno, Mitsunori (Takeda Pharmaceutical Company Limited, Japan). PCT Int. Appl. WO 2009157196 A1 20091230, 252pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LB, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2009-JP2902 20090624. PRIORITY: JP 2008-166467 20080625.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title comps. [I; A = each (un)substituted CONH or NHCO; B = H or substituent; ring Cy1 = benzene or 6-membered N-containing aromatic heterocyclic ring optionally having substituents in addition to A-B; X1, X2, X3 = CRX1; N; Rx = H, halo, lower alkyl, halo-lower alkyl; ring Cy2 = each (un)substituted C5-7 carbocyclic or 5- to 7-membered heterocyclic ring containing 1 or 2 heteroatom(s) selected from N, O, and S; Z = C, N; L = a bond, (CH2)n, L1, L1-CH2, CH2-L1; n = 1, 2; L1 = O, (un)substituted NH, S(O)m; m = 0-2 integer; ring Cy3 = each (un)substituted benzene or 6-membered aromatic heterocyclic ring] or salts thereof. These comps. have

GPR52 agonist activity and serve as agents for preventing or treating mental diseases such as schizophrenia. Thus, a solution of 3-[1-(2,4-dichlorophenyl)-2,3-dihydro-1H-indol-6-yl]benzoic acid 70, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 42.2, and

HOBT 29.7 mg in 1 mL DMF was treated with 24.0 µL N,N-dimethylethane-1,2-diamine and stirred at room temperature for 16 h to give, after workup and silica gel chromatog., 61% 3-[1-(2,4-dichlorophenyl)-2,3-dihydro-1H-indol-6-yl]-N-[2-(dimethylamino)ethyl]benzamide (II). II, N-(2-cyanoethyl)-3-[7-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]benzamide (III), and 3-[3-(2,4-dichlorophenyl)-2,3-dihydro-1H-inden-5-yl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide (IV) showed 87, 40, and 91% GPR52 agonist activity, resp., in an assay for increasing the production of cellular cAMP in CHO cells expressing human GPR52. A tablet formulation containing II was described.

IT 1202500-84-2P, N-(2-Cyanoethyl)-3-[1-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzamide, 1202500-86-4P, 3-[1-(2,4-Dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-(2-

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS ON STN
2008:806242 Document No. 149:119581 Kinase inhibitors for preventing or treating pathogen infection and method of use thereof. Kalman, Daniel (Emory University, USA). PCT Int. Appl. WO 2008079460 A2 20080703, 73pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-US77578 20070905. PRIORITY: US 2006-824540P 20060905.

AB The invention provides comps. and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic


infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likelihood of engendering resistance as compared to conventional antibiotics and antiviral drugs. The invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.

IT 1001083-65-3 1001083-66-4 1001083-67-5
1001083-68-6 1001083-69-7 1001083-78-8
1001083-79-9 1001083-84-6 1001083-85-7
1001083-86-8 1001083-87-9 1001083-88-0
1001083-89-1 1001083-90-4 1001083-91-5
1001083-92-6 1001083-93-7 1001083-95-9
1001084-05-4 1001084-07-6 1001084-08-7
1001084-09-8 1001084-10-1 1001084-11-2
1001084-12-3 1001084-13-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 1001083-65-3 CAPLUS
(kinase inhibitors for preventing or treating pathogen infection)

CN Acetamide, N-[3-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001083-66-4 CAPLUS
CN Acetamide, N-[3-[3-(4-fluoro-3-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2010 ACS ON STN (Continued)
hydroxyethyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclylbenzamides, indanylbenzamides, and indanylpyridinecarboxamides as G protein-coupled receptor GPR52 agonists for preventing and treating schizophrenia)


RN 1202500-84-2 CAPLUS
CN Benzamide, N-(2-cyanoethyl)-3-[1-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 1202500-86-4 CAPLUS
CN Benzamide, 3-[1-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS ON STN (Continued)




RN 1001083-67-5 CAPLUS
CN Acetamide, N-[3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 1001083-68-6 CAPLUS
CN Acetamide, N-[3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001083-69-7 CAPLUS
CN Benzoic acid, 4-[6-[3-(acetylamino)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)




RN 1001083-78-8 CAPLUS
CN Benzoic acid, 4-[6-[3-(aminocarbonyl)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)

10587989.trn


L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-79-9 CAPLUS
CN Benzoic acid, 3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)



RN 1001083-84-6 CAPLUS
CN Benzoic acid, 4-[6-[4-(acetylamino)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)




RN 1001083-85-7 CAPLUS
CN Acetamide, N-[4-[3-(4-bromo-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001083-86-8 CAPLUS
CN Acetamide, N-[4-[3-(4-bromo-2-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-91-5 CAPLUS
CN Acetamide, N-[4-[3-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 1001083-92-6 CAPLUS
CN Acetamide, N-[4-[3-(4-bromophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001083-93-7 CAPLUS
CN Acetamide, N-[4-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001083-95-9 CAPLUS
CN Acetamide, N-[4-[3-(2,4-dimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-87-9 CAPLUS
CN Acetamide, N-[4-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 1001083-88-0 CAPLUS
CN Acetamide, N-[4-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001083-89-1 CAPLUS
CN Acetamide, N-[4-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001083-90-4 CAPLUS
CN Acetamide, N-[4-[3-(3,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001084-05-4 CAPLUS
CN Acetamide, N-[3-[3-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 1001084-07-6 CAPLUS
CN Acetamide, N-[3-[3-(4-bromo-2-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001084-08-7 CAPLUS
CN Acetamide, N-[3-[3-(4-bromo-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001084-09-8 CAPLUS
CN Acetamide, N-[3-[3-(4-bromo-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)

10587989.trn


L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001084-10-1 CAPLUS
CN Acetamide,
N-[3-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)



RN 1001084-11-2 CAPLUS
CN Acetamide,
N-[3-[3-(4-bromophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)



RN 1001084-12-3 CAPLUS
CN Acetamide,
N-[3-[3-(4-ethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)




RN 1001084-13-4 CAPLUS
CN Acetamide, N-[3-[3-(2,4-dimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
2008:42473 Document No. 148:1447610 Substituted 1H-pyrazolo[3,4-b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as c-kit inhibitors. Bornmann, William; Maxwell, David; Pal, Ashutosh; Peng, Zhenghong; Estrov, Zeev (Board of Regents, The University of Texas System, USA). PCT Int. Appl. WO 2008005877 A2 20080110, 108pp. DESIGNATED STATES: W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-US72555 20070629. PRIORITY: US 2006-806385P 20060630; US 2006-807381P 20060714.
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to substituted 1H-pyrazolo[3,4-b]pyridine derivs.
I, processes for preparing them, pharmaceutical preps. comprising them, and their pharmaceutical use. I are c-kit (CD117) inhibitors, useful in the treatment of, e.g., cancer. In compds. I, m and n are independently 1 to 5; R1 is H, CN, halo, alkoxycarbonyl, or (un)substituted alk(yl)oxy; R2 and R3 are independently H, (un)substituted alk(yl)enyl, or (hetero)aryl, etc.; with proviso. For instance, the invention compound
II was prepared from 2,6-dichloronicotinic acid in 3 steps (about 21% overall yield), and gave an EC50 value of about 100 nM in the cell line OCI/AML3.
IT 1001084-34-9P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazolopyridine derivs. as c-kit inhibitors)
RN 1001084-34-9 CAPLUS
CN Acetamide, N-[3-[3-[4-(4-methyl-1-piperazinyl)phenyl]-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)




IT 1001083-65-3P 1001083-66-4P 1001083-67-5P
1001083-68-6P 1001083-69-7P 1001083-77-7P
1001083-78-8P 1001083-79-9P 1001083-83-5P
1001083-84-6P 1001083-85-7P 1001083-86-8P
1001083-87-9P 1001083-88-0P 1001083-89-1P

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
1001083-90-4P 1001083-91-5P 1001083-92-6P
1001083-93-7P 1001083-94-8P 1001083-95-9P
1001084-05-4P 1001084-07-6P 1001084-08-7P
1001084-09-8P 1001084-10-1P 1001084-11-2P
1001084-12-3P 1001084-13-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of pyrazolopyridine derivs. as c-kit inhibitors)


RN 1001083-65-3 CAPLUS
CN Acetamide, N-[3-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)



RN 1001083-66-4 CAPLUS
CN Acetamide, N-[3-[3-(4-fluoro-3-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)




RN 1001083-67-5 CAPLUS
CN Acetamide,
N-[3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)




RN 1001083-68-6 CAPLUS
CN Acetamide, N-[3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)

10587989.trn


L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-69-7 CAPLUS
CN Benzoic acid,
4-[6-[3-(acetylamino)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
, ethyl ester (CA INDEX NAME)



RN 1001083-77-7 CAPLUS
CN Benzoic acid,
4-[6-[3-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-1H-
pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)




RN 1001083-78-8 CAPLUS
CN Benzoic acid, 4-[6-[3-(aminocarbonyl)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-
yl]-, ethyl ester (CA INDEX NAME)




RN 1001083-79-9 CAPLUS
CN Benzamide, 3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]- (CA
INDEX NAME)


L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-87-9 CAPLUS
CN Acetamide,
N-[4-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)



RN 1001083-88-0 CAPLUS
CN Acetamide, N-[4-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)




RN 1001083-89-1 CAPLUS
CN Acetamide,
N-[4-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)




RN 1001083-90-4 CAPLUS
CN Acetamide, N-[4-[3-(3,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-83-5 CAPLUS
CN Acetamide, N-[4-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)



RN 1001083-84-6 CAPLUS
CN Benzoic acid,
4-[6-[4-(acetylamino)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
, ethyl ester (CA INDEX NAME)




RN 1001083-85-7 CAPLUS
CN Acetamide, N-[4-[3-(4-bromo-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)




RN 1001083-86-8 CAPLUS
CN Acetamide, N-[4-[3-(4-bromo-2-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-91-5 CAPLUS
CN Acetamide, N-[4-[3-(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)



RN 1001083-92-6 CAPLUS
CN Acetamide,
N-[4-[3-(4-bromophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)




RN 1001083-93-7 CAPLUS
CN Acetamide, N-[4-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)




RN 1001083-94-8 CAPLUS
CN Acetamide,
N-[4-[3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)

10587989.trn


L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001083-95-9 CAPLUS
CN Acetamide, N-[4-[(2,4-dimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 1001084-05-4 CAPLUS
CN Acetamide, N-[3-[(2,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001084-07-6 CAPLUS
CN Acetamide, N-[3-[(4-bromo-2-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 1001084-08-7 CAPLUS
CN Acetamide, N-[3-[(3,4-dichlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(CA INDEX NAME)




RN 1001084-13-4 CAPLUS
CN Acetamide, N-[3-[(2,4-dimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1001084-09-8 CAPLUS
CN Acetamide, N-[3-[(4-bromo-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 1001084-10-1 CAPLUS
CN Acetamide,
N-[3-[(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)



RN 1001084-11-2 CAPLUS
CN Acetamide,
N-[3-[(4-bromophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)





RN 1001084-12-3 CAPLUS
CN Acetamide,
N-[3-[(4-ethylphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]-
(CA INDEX NAME)

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
2007:150614 Document No. 146:2293360 Preparation of substituted
7-azaindoles

as kinase inhibitors, and their compositions and use for treatment of cancer. Bjerger, Kristen; Nair, Anil; Patek, Marcel; Dodson, Mark; Ackerman, Berrier Martha; Smrcina, Martin; Leroy, Vincent; Bacque, Eric; Tabart, Michel; Ronan, Baptiste (Aventis Pharma SA, Fr.). Fr. Demande FR 2889526 A1 20070209, 48pp. (French). CODEN: FRXXBL. APPLICATION: FR 2005-8316 20050804.

GI



II

AB Title compds. I [A, Ar = independently (un)substituted heteroaryl, heterocyclyl, cycloalkyl; L = NH, CONH, NHCO, NHSO2, COCH2NH, etc.; X = N,
NO; R3 = H, NHMR'3; M = a bond, CO, CONH, CS, CSNH, SO2; R'3 = H, (un)substituted alkyl, heteroaryl, cycloalkyl, etc.; R4 = H, halo, OH and
derivs., alkyl, etc.; R5 = H, halo, CN, NH2 and derivs., CO2H and
derivs., etc.] were prepared as kinase inhibitors for treatment especially of cancer.


E.g., a multi-step synthesis starting from 2-aminothiazole-5-carboxaldehyde and 2-fluoro-5-(trifluoromethyl)phenyl isocyanate was given for azaindole II. Azaindole II inhibited FAK, KDR and Tie2 kinases with an IC50 of 343 nM, 83 nM, and 1 nM, resp. Thus, I and their pharmaceutical compns., are useful as anticancer agents (no data).

IT 924667-93-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azaindoles as FAK, KDR and Tie2 kinase inhibitors and their use for treating cancer)

RN 924667-93-6 CAPLUS
CN Urea,
N-[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-N'-(2-fluoro-5-


10587989.trn

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 924667-94-7P 924667-98-1P 924667-99-2P
924668-00-8P 924668-25-7P 924668-26-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of azaindoles as FAK, KDR and Tie2 kinase inhibitors and
their use for treating cancer)


RN 924667-94-7 CAPLUS
CN 3-Thiophenecarboxamide, N-[6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (CA INDEX NAME)



RN 924667-98-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,


6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-
(CA INDEX NAME)

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 924667-99-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,


6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-
methyl- (CA INDEX NAME)



RN 924668-00-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,


6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-
[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 924668-25-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,


6-[3-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-
methyl- (CA INDEX NAME)



RN 924668-26-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-4-carboxamide,

6-[3-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-N-
[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10587989.trn

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
 2005:732653 Document No. 143:2119090 Preparation of fused heteroaryl derivatives as p38 kinase inhibitors. Barker, Michael David; Hamblin, Julie Nicole; Jones, Katherine Louise; Patel, Vipulkumar Kantibhai; Swanson, Stephen; Walker, Ann Louise (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 2005073232 A1 20050811, 88 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-GB274 20050127. PRIORITY: GB 2004-2137 20040130.

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring containing one or two heteroatoms independently selected from O and N;
 R1 = Me
 or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo;
 W
 = N or NO and Z = CH or W = CH and Z = N or NO or W and Z are each independently selected from N and NO] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by coupling of N-cyclopropyl-4-methyl-3-(1H-pyrazolo[3,4-c]pyridin-5-yl)benzamide (preparation given) with isopropylsulfonylchloride. The activity of I was evaluated


in
 fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 µM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compns. comprising I are disclosed.

IT 862169-93-5P 862169-94-6P 862169-96-8P
 862170-24-9P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
 RN 862169-93-5 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-94-6 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-(1-phenyl-1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)




RN 862169-96-8 CAPLUS
 CN Benzamide, N-cyclopropyl-3-[1-(2-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]-4-methyl- (CA INDEX NAME)




RN 862170-24-9 CAPLUS
 CN Benzamide, 3-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)-N-cyclopropyl-4-methyl- (CA INDEX NAME)

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




IT 862169-84-4P 862169-85-5P 862169-86-6P
 862169-87-7P 862169-88-8P 862169-89-9P
 862169-90-2P 862169-91-3P 862169-92-4P
 862169-95-7P 862169-97-9P 862169-98-0P
 862169-99-1P 862170-00-1P 862170-01-2P
 862170-02-3P 862170-03-4P 862170-04-5P
 862170-05-6P 862170-06-7P 862170-07-8P
 862170-08-9P 862170-09-0P 862170-10-3P
 862170-11-4P 862170-12-5P 862170-13-6P
 862170-14-7P 862170-15-8P 862170-16-9P
 862170-17-0P 862170-18-1P 862170-19-2P
 862170-20-5P 862170-21-6P 862170-22-7P
 862170-23-8P 862170-25-0P 862170-26-1P
 862170-27-2P 862170-28-3P 862170-29-4P
 862170-30-7P 862170-31-8P 862170-32-9P
 862170-33-0P 862170-34-1P 862170-35-2P
 862170-36-3P 862170-37-4P 862170-38-5P
 862170-39-6P 862170-40-9P 862170-41-0P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
 RN 862169-84-4 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-[1-[(1-methylethyl)sulfonyl]-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-85-5 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-86-6 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-87-7 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-88-8 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)

10587989.trn


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-89-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[3-(3-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-90-2 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-91-3 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(1-methylethylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862169-98-0 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-fluorophenyl)-6-oxido-1H-pyrazolo[3,4-c]pyridin-5-yl]-4-methyl- (CA INDEX NAME)



RN 862169-99-1 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(4-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-00-1 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-01-2 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-4-methyl- (CA INDEX NAME)


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-92-4 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 862169-95-7 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-6-oxido-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-97-9 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-(6-oxido-1-phenyl-1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862170-02-3 CAPLUS
CN Benzoic acid, 4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)




RN 862170-03-4 CAPLUS
CN Benzanide, N-ethyl-3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-04-5 CAPLUS
CN Benzanide, N-ethyl-3-[3-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)

10587989.trn


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-05-6 CAPLUS
CN Benzamide,
3-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-06-7 CAPLUS
CN Benzamide,
N-ethyl-3-[3-(3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
4-methyl- (CA INDEX NAME)




L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 862170-10-3 CAPLUS
CN Benzamide,
3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
N-ethyl-4-methyl- (CA INDEX NAME)



RN 862170-11-4 CAPLUS
CN Benzamide,
3-[3-[(3-chlorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-
ethyl-4-methyl- (CA INDEX NAME)




RN 862170-12-5 CAPLUS
CN Benzamide,
N-ethyl-3-[3-[(4-fluorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-
6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-13-6 CAPLUS

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-07-8 CAPLUS
CN Benzamide, N-ethyl-3-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-08-9 CAPLUS
CN Benzamide,
3-[3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-09-0 CAPLUS
CN Benzamide, 3-[3-[(3,4-difluorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-6-
yl]-N-ethyl-4-methyl- (CA INDEX NAME)




L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN Benzamide,
N-ethyl-3-[3-(3-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
4-methyl- (CA INDEX NAME)



RN 862170-14-7 CAPLUS
CN Benzamide,
3-[3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-15-8 CAPLUS
CN Benzamide, N-ethyl-3-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-16-9 CAPLUS
CN Benzamide,
N-ethyl-3-[3-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-4-

10587989.trn


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
methyl- (CA INDEX NAME)




RN 862170-17-0 CAPLUS
CN Benzamide,
3-[3-(4-cyanophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-18-1 CAPLUS
CN Benzamide,
N-ethyl-3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-
methyl- (CA INDEX NAME)




L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-23-8 CAPLUS
CN Benzamide, 3-fluoro-5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 862170-25-0 CAPLUS
CN Benzamide, 3-[3-(acetylamino)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-
cyclopropyl-4-methyl- (CA INDEX NAME)




RN 862170-26-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-[3-[(4-fluorobenzoyl)amino]-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-27-2 CAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[3-[(2-methyl-1-oxopropyl)amino]-1H-

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-19-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)



RN 862170-20-5 CAPLUS
CN Benzamide,
3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 862170-21-6 CAPLUS
CN Benzamide, 3-fluoro-5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 862170-22-7 CAPLUS
CN Benzamide,
3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-28-3 CAPLUS
CN Benzamide, 3-[3-[(cyclopentylcarbonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-
yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 862170-29-4 CAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[3-[(1-oxopropyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-30-7 CAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[3-[(4-methylbenzoyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-31-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-[3-[(4-methoxybenzoyl)amino]-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)

10587989.trn


L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-32-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[6-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (CA INDEX NAME)




RN 862170-33-0 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(3-[(propylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)- (CA INDEX NAME)




RN 862170-34-1 CAPLUS
CN Benamide, N-cyclopropyl-3-[(3-[(4-fluorophenyl)sulfonyl]amino)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-39-6 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(2-thienylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)



RN 862170-40-9 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(1-methylethyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-41-0 CAPLUS
CN Benamide, 3-(3-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)-N-cyclopropyl-4-methyl- (CA INDEX NAME)




IT 862170-43-2P 862170-44-3P 862170-48-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-35-2 CAPLUS
CN Benamide, N-cyclopropyl-3-[(3-[(ethylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methyl- (CA INDEX NAME)



RN 862170-36-3 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(3-[(propylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)- (CA INDEX NAME)




RN 862170-37-4 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(3-[(3-thienylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)- (CA INDEX NAME)




RN 862170-38-5 CAPLUS
CN Benamide, N-cyclopropyl-3-[(3-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino)-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methyl- (CA INDEX NAME)

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-43-2 CAPLUS
CN Benamide, 3-(1-acetyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 862170-44-3 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-(1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)




RN 862170-48-7 CAPLUS
CN Benamide, N-cyclopropyl-3-fluoro-4-methyl-5-(1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)




10587989.trn

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
 2003:135138 Document No. 139:68020 Facile generation of pyridopyrazoles:
 synthesis of
 3-amino-4-aryl-6-[p-(benzoylamino)phenyl]-1-phenylpyrido[2,3-
 d]pyrazoles. Nagar, D. N.; Mehta, Tushar; Shah, V. H. (Chemical Research
 Laboratory, Chemistry Department, Saurashtra University, Rajkot, 360 005,
 India). Journal of the Institution of Chemists (India), 74(4), 132-134
 (English) 2002. CODEN: JOICA7. ISSN: 0020-3254. OTHER SOURCES:
 CASREACT
 139:6802. Publisher: Institution of Chemists (India).
 GI




AB Title compds. I [R = cinnamyl, furfuryl, (un)substituted phenyl] were
 prepared by cyclocondensation of amino nitriles II with PhNHNH2. I
 showed
 moderate antibacterial and antifungal activity.
 IT 533901-49-4P 533901-50-7P 533901-51-8P
 533901-52-9P 533901-53-0P 533901-54-1P
 533901-55-2P 533901-56-3P 533901-57-4P
 533901-58-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation and antibacterial and antifungal activity of)
 RN 533901-49-4 CAPLUS
 CN Benzamide, N-[4-(3-amino-1,4-diphenyl-1H-pyrazolo[3,4-b]pyridin-6-
 yl)phenyl]- (CA INDEX NAME)


L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 533901-50-7 CAPLUS
 CN Benzamide, N-[4-(3-amino-4-(2-chlorophenyl)-1-phenyl-1H-pyrazolo[3,4-
 b]pyridin-6-yl)phenyl]- (CA INDEX NAME)




RN 533901-51-8 CAPLUS
 CN Benzamide, N-[4-(3-amino-1-phenyl-4-(3-phenyl-2-propen-1-yl)-1H-
 pyrazolo[3,4-b]pyridin-6-yl)phenyl]- (CA INDEX NAME)




RN 533901-52-9 CAPLUS
 CN Benzamide, N-[4-(3-amino-4-(2-furanylmethyl)-1-phenyl-1H-pyrazolo[3,4-
 b]pyridin-6-yl)phenyl]- (CA INDEX NAME)


L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 533901-53-0 CAPLUS
 CN Benzamide, N-[4-(3-amino-4-(2-hydroxyphenyl)-1-phenyl-1H-pyrazolo[3,4-
 b]pyridin-6-yl)phenyl]- (CA INDEX NAME)




RN 533901-54-1 CAPLUS
 CN Benzamide, N-[4-(3-amino-4-(4-hydroxy-3-methoxyphenyl)-1-phenyl-1H-
 pyrazolo[3,4-b]pyridin-6-yl)phenyl]- (CA INDEX NAME)




RN 533901-55-2 CAPLUS
 CN Benzamide,
 N-[4-(3-amino-4-[4-(methylthio)phenyl]-1-phenyl-1H-pyrazolo[3,4-
 b]pyridin-6-yl)phenyl]- (CA INDEX NAME)


L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 533901-56-3 CAPLUS
 CN Benzamide, N-[4-(3-amino-4-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-
 b]pyridin-6-yl)phenyl]- (CA INDEX NAME)




RN 533901-57-4 CAPLUS
 CN Benzamide, N-[4-(3-amino-4-(2-nitrophenyl)-1-phenyl-1H-pyrazolo[3,4-
 b]pyridin-6-yl)phenyl]- (CA INDEX NAME)



RN 533901-58-5 CAPLUS
 CN Benzamide, N-[4-(3-amino-4-(3-phenoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-
 b]pyridin-6-yl)phenyl]- (CA INDEX NAME)



10587989.trn

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
2003:135137 Document No. 139:68010 Facile generation of pyridopyrazoles:
synthesis of 3-amino-4-aryl-6-(p-benzamidophenyl)pyrido[2,3-d]-1H-
pyrazoles. Nagar, D. N.; Mehta, Tushar; Shah, V. H. (Chemical Research
Laboratory, Chemistry Department, Saurashtra University, Rajkot, 360 005,
India). Journal of the Institution of Chemists (India), 74(4), 129-131
(English) 2002. CODEN: JOICA7. ISSN: 0020-3254. OTHER SOURCES:

CASREACT 139:6801. Publisher: Institution of Chemists (India).
GI



AB Title compds. I [R = cinnamyl, furfuryl, (un)substituted phenyl] were
prepared by heterocyclization reaction of aminopyridinecarbonitriles II
with


hydrazine hydrate. I showed moderate antibacterial and antifungal
activity.

IT 535930-87-1P 535930-88-2P 535930-89-3P
535930-90-6P 535930-91-7P 535930-92-8P
535930-93-9P 535930-94-0P 535930-95-1P
535930-96-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation and antibacterial and antifungal activity of)

RN 535930-87-1 CAPLUS
CN Benzamide,
N-[4-(3-amino-4-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-
(CA INDEX NAME)


L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 535930-88-2 CAPLUS
CN Benzamide, N-[4-[3-amino-4-(2-chlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)




RN 535930-89-3 CAPLUS
CN Benzamide, N-[4-[3-amino-4-(3-phenyl-2-propen-1-yl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 535930-90-6 CAPLUS
CN Benzamide, N-[4-[3-amino-4-(2-furanylmethyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)


L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 535930-91-7 CAPLUS
CN Benzamide, N-[4-[3-amino-4-(2-hydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-
yl]phenyl]- (CA INDEX NAME)




RN 535930-92-8 CAPLUS
CN Benzamide, N-[4-[3-amino-4-(4-hydroxy-3-methoxyphenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 535930-93-9 CAPLUS
CN Benzamide, N-[4-[3-amino-4-[4-(methylthio)phenyl]-1H-pyrazolo[3,4-
b]pyridin-6-yl]phenyl]- (CA INDEX NAME)

10587989.trn


L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 535930-94-0 CAPLUS
CN Benzamide, N-[4-{3-amino-4-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl}phenyl]- (CA INDEX NAME)




RN 535930-95-1 CAPLUS
CN Benzamide, N-[4-{3-amino-4-(2-nitrophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl}phenyl]- (CA INDEX NAME)



RN 535930-96-2 CAPLUS
CN Benzamide, N-[4-{3-amino-4-(3-phenoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl}phenyl]- (CA INDEX NAME)

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10587989.trn

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

L15 61 S L6
L16 6 S L15 AND P38
L17 5 S L16 NOT L8

=> s l16 and l8

L18 1 L16 AND L8

=> d cbib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

10587989.trn

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN
 2005:732653 Document No. 143:2119090 Preparation of fused heteroaryl derivatives as p38 kinase inhibitors. Barker, Michael David; Hamblin, Julie Nicole; Jones, Katherine Louise; Patel, Vipulkumar Kantibhai; Swanson, Stephen; Walker, Ann Louise (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 2005073232 A1 20050811, 88 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,

BY,

BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.
 APPLICATION: WO 2005-GB274 20050127. PRIORITY: GB 2004-2137 20040130.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring containing one or two heteroatoms independently selected from O and N; R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo;

W = N or NO and Z = CH or W = CH and Z = N or NO or W and Z are each independently selected from N and NO] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by coupling of N-cyclopropyl-4-methyl-3-(1H-pyrazolo[3,4-c]pyridin-5-yl)benzamide (preparation given) with isopropylsulfonylchloride. The activity of I was evaluated


in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 µM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compds. comprising I are disclosed.

IT 862169-93-5P 862169-94-6P 862169-96-8P
 862170-24-9P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
 RN 862169-93-5 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-94-6 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-(1-phenyl-1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)




RN 862169-96-8 CAPLUS
 CN Benzamide, N-cyclopropyl-3-[1-(2-fluorophenyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]-4-methyl- (CA INDEX NAME)



RN 862170-24-9 CAPLUS
 CN Benzamide, 3-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)-N-cyclopropyl-4-methyl- (CA INDEX NAME)


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 862169-84-4P 862169-85-5P 862169-86-6P
 862169-87-7P 862169-88-8P 862169-89-9P
 862169-90-2P 862169-91-3P 862169-92-4P
 862169-95-7P 862169-97-9P 862169-98-0P
 862169-99-1P 862170-00-1P 862170-01-2P
 862170-02-3P 862170-03-4P 862170-04-5P
 862170-05-6P 862170-06-7P 862170-07-8P
 862170-08-9P 862170-09-0P 862170-10-3P
 862170-11-4P 862170-12-5P 862170-13-6P
 862170-14-7P 862170-15-8P 862170-16-9P
 862170-17-0P 862170-18-1P 862170-19-2P
 862170-20-5P 862170-21-6P 862170-22-7P
 862170-23-8P 862170-25-0P 862170-26-1P
 862170-27-2P 862170-28-3P 862170-29-4P
 862170-30-7P 862170-31-8P 862170-32-9P
 862170-33-0P 862170-34-1P 862170-35-2P
 862170-36-3P 862170-37-4P 862170-38-5P
 862170-39-6P 862170-40-9P 862170-41-0P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
 RN 862169-84-4 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-[1-[(1-methylethyl)sulfonyl]-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-85-5 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-86-6 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-87-7 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-88-8 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)

10587989.trn


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-89-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[3-(3-thienylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-90-2 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-91-3 CAPLUS
CN Benzanide,
N-cyclopropyl-3-fluoro-4-methyl-5-[1-(1-methylethylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862169-98-0 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-fluorophenyl)-6-oxido-1H-pyrazolo[3,4-c]pyridin-5-yl]-4-methyl- (CA INDEX NAME)



RN 862169-99-1 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(4-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-00-1 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-01-2 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-4-methyl- (CA INDEX NAME)


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862169-92-4 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 862169-95-7 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-6-oxido-1H-pyrazolo[3,4-c]pyridin-5-yl]- (CA INDEX NAME)




RN 862169-97-9 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-(6-oxido-1-phenyl-1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 862170-02-3 CAPLUS
CN Benzoic acid, 4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)




RN 862170-03-4 CAPLUS
CN Benzanide,
3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)




RN 862170-04-5 CAPLUS
CN Benzanide,
N-ethyl-3-[3-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)

10587989.trn


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-05-6 CAPLUS
CN Benzamide,
3-[3-(4-cyanophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-06-7 CAPLUS
CN Benzamide,
N-ethyl-3-[3-(3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
4-methyl- (CA INDEX NAME)




L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 862170-10-3 CAPLUS
CN Benzamide,
3-[3-(4-chloro-3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
N-ethyl-4-methyl- (CA INDEX NAME)



RN 862170-11-4 CAPLUS
CN Benzamide,
3-[3-[(3-chlorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-
ethyl-4-methyl- (CA INDEX NAME)




RN 862170-12-5 CAPLUS
CN Benzamide,
N-ethyl-3-[3-[(4-fluorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-
6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-13-6 CAPLUS

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-07-8 CAPLUS
CN Benzamide, N-ethyl-3-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-08-9 CAPLUS
CN Benzamide,
3-[3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-09-0 CAPLUS
CN Benzamide, 3-[3-[(3,4-difluorophenyl)methyl]-1H-pyrazolo[4,3-c]pyridin-6-
yl]-N-ethyl-4-methyl- (CA INDEX NAME)




L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN Benzamide,
N-ethyl-3-[3-(3-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
4-methyl- (CA INDEX NAME)



RN 862170-14-7 CAPLUS
CN Benzamide,
3-[3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-15-8 CAPLUS
CN Benzamide, N-ethyl-3-[3-(3-fluoro-4-methylphenyl)-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-16-9 CAPLUS
CN Benzamide,
N-ethyl-3-[3-(3-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-4-

10587989.trn


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
methyl- (CA INDEX NAME)




RN 862170-17-0 CAPLUS
CN Benamide,
3-[3-(4-cyanophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-N-ethyl-4-
methyl- (CA INDEX NAME)




RN 862170-18-1 CAPLUS
CN Benamide,
N-ethyl-3-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-
methyl- (CA INDEX NAME)




L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-23-8 CAPLUS
CN Benamide, 3-fluoro-5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazolo[4,3-
c]pyridin-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 862170-25-0 CAPLUS
CN Benamide, 3-[3-(acetylamino)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-
cyclopropyl-4-methyl- (CA INDEX NAME)




RN 862170-26-1 CAPLUS
CN Benamide, N-cyclopropyl-3-[3-[(4-fluorobenzoyl)amino]-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




RN 862170-27-2 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[3-[(2-methyl-1-oxopropyl)amino]-1H-

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-19-2 CAPLUS
CN Benamide, N-cyclopropyl-3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)



RN 862170-20-5 CAPLUS
CN Benamide,
3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 862170-21-6 CAPLUS
CN Benamide, 3-fluoro-5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 862170-22-7 CAPLUS
CN Benamide,
3-fluoro-5-[3-(4-fluorophenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-
4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-28-3 CAPLUS
CN Benamide, 3-[3-[(cyclopentylcarbonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-
yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 862170-29-4 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[3-[(1-oxopropyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-30-7 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[3-[(4-methylbenzoyl)amino]-1H-
pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-31-8 CAPLUS
CN Benamide, N-cyclopropyl-3-[3-[(4-methoxybenzoyl)amino]-1H-pyrazolo[3,4-
b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)

10587989.trn


L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-32-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[6-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (CA INDEX NAME)




RN 862170-33-0 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(3-[(propylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)- (CA INDEX NAME)




RN 862170-34-1 CAPLUS
CN Benamide, N-cyclopropyl-3-[(3-[(4-fluorophenyl)sulfonyl]amino)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-methyl- (CA INDEX NAME)




L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 862170-39-6 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(2-thienylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)



RN 862170-40-9 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(1-methylethyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl]- (CA INDEX NAME)




RN 862170-41-0 CAPLUS
CN Benamide, 3-(3-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)-N-cyclopropyl-4-methyl- (CA INDEX NAME)




IT 862170-43-2P 862170-44-3P 862170-48-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-35-2 CAPLUS
CN Benamide, N-cyclopropyl-3-[(3-[(ethylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methyl- (CA INDEX NAME)



RN 862170-36-3 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(3-[(propylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)- (CA INDEX NAME)




RN 862170-37-4 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-[(3-[(3-thienylsulfonyl)amino]-1H-pyrazolo[3,4-b]pyridin-6-yl)- (CA INDEX NAME)




RN 862170-38-5 CAPLUS
CN Benamide, N-cyclopropyl-3-[(3-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino)-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methyl- (CA INDEX NAME)

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 862170-43-2 CAPLUS
CN Benamide, 3-(1-acetyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 862170-44-3 CAPLUS
CN Benamide, N-cyclopropyl-4-methyl-3-(1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)



RN 862170-48-7 CAPLUS
CN Benamide, N-cyclopropyl-3-fluoro-4-methyl-5-(1H-pyrazolo[3,4-c]pyridin-5-yl)- (CA INDEX NAME)



10587989.trn

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010


L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010


L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

10587989.trn

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 2008:1138529 Document No. 149:5482550 Kinase array design, back to front:
 Biaryl amides. Baldwin, Ian; Bamborough, Paul; Haslam, Claudine G.;
 Hunjan, Suchete S.; Longstaff, Tim; Mooney, Christopher J.; Patel, Shila;
 Quinn, Jo; Somers, Don O. (Medicines Research Centre, GlaxoSmithKline
 R&D,
 Stevenage, Hertfordshire, SG1 2NY, UK). Bioorganic & Medicinal Chemistry
 Letters, 18(19), 5285-5289 (English) 2008. CODEN: BMCLE8. ISSN:
 0960-894X. OTHER SOURCES: CASREACT 149:548255. Publisher: Elsevier
 Ltd.
 AB New kinase inhibitors can be found by synthesis of targeted arrays of
 compds. designed using system-based knowledge as well as through
 screening
 focused or diverse compds. Most array strategies aim to add
 functionality
 to a fragment that binds in the purine subpocket of the ATP-site. Here,
 an alternative pharmacophore-guided array approach is described which set
 out to discover novel purine subpocket-binding groups. Results are shown
 for p38.alpha. and cFMS kinase, for which multiple distinct
 series with nanomolar potency were discovered. Some of the compds.
 showed
 potency in cell-based assays and good pharmacokinetic properties.
 IT 651780-03-9 1082072-22-7
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (generation of biaryl amide kinase inhibitor lead compds. by addition
 of
 functionality to compds. already binding in the lipophilic interiors
 of
 kinase ATP-binding sites to find structural fragments binding in the
 purine subpockets)
 RN 651780-03-9 CAPLUS
 CN Benzamide, N-cyclopropyl-3-(1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)




RN 1082072-22-7 CAPLUS
 CN Benzamide, 3-(1H-indazol-6-yl)-4-methyl-N-[3-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 2005:732643 Document No. 143:1939990 Preparation of fused heteroaryl
 derivatives as p38 kinase inhibitors. Campos, Sebastien Andre;
 Swanson, Stephen; Walker, Ann Louise (Smithkline Beecham Corporation,
 USA). PCT Int. Appl. WO 2005073219 A1 20050811, 59 pp. DESIGNATED
 STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI,
 CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE,
 NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO
 2005-GB281 20050127. PRIORITY: GB 2004-2140 20040130.
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1
 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 =
 H,
 cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo]
 and their pharmaceutically acceptable salts, are prepared and disclosed
 as
 p38 kinase inhibitors. Thus, e.g., II was prepared by coupling of
 N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide (preparation
 given) with 2-(bromomethyl)tetrahydro-2H-pyran. The activity of I was
 evaluated in fluorescence anisotropy kinase binding assays and it was
 revealed that compds. of the invention displayed IC50 values of <10 µM
 or pKi values of >6. I as p38 kinase inhibitor should prove
 useful in the treatment of disease states mediated by p38
 kinase. Pharmaceutical compns. comprising I are disclosed.
 IT 861972-48-7P 861972-49-8P 861972-50-1P
 861972-51-2P 861972-52-3P 861972-53-4P
 861972-54-5P 861972-55-6P 861972-56-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
 RN 861972-48-7 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(tetrahydro-2H-pyran-2-
 yl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861972-49-8 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(tetrahydro-2-

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 furanyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861972-50-1 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[[4-(phenylmethyl)-2-
 morpholinyl]methyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861972-51-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-3-fluoro-2-
 methylphenyl]-1H-indazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 861972-52-3 CAPLUS
 CN Benzamide,
 N-ethyl-4-methyl-3-[3-(tetrahydro-3-furanyl)-1H-indazol-6-yl]-
 (CA INDEX NAME)

10587989.trn


L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861972-53-4 CAPLUS
CN Benamide, N-ethyl-3-fluoro-4-methyl-5-[3-(tetrahydro-3-furanyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861972-54-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-indazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 861972-55-6 CAPLUS
CN 1-Piperazinecarboxamide, N-ethyl-4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-indazol-3-yl]- (CA INDEX NAME)


L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861905-36-4 CAPLUS
CN Benamide, N-ethyl-3-(1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)




RN 861905-37-5 CAPLUS
CN Benamide, N-ethyl-3-(3-iodo-1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)




RN 861905-40-0 CAPLUS
CN Benamide, N-ethyl-3-fluoro-5-(3-iodo-1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)

L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 861972-56-7 CAPLUS
CN 1-Piperidinecarboxamide, N-ethyl-4-[6-[5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-3-yl]- (CA INDEX NAME)




IT 651780-48-2P 651781-09-8P 861905-36-4P
861905-37-5P 861905-40-0P 861972-61-4P
861972-62-5P 861972-63-6P 861972-64-7P
861972-65-8P 861972-66-9P 861972-67-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
RN 651780-48-2 CAPLUS
CN Benamide, N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methyl- (CA INDEX NAME)




RN 651781-09-8 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-


L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861972-61-4 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-indazol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 861972-62-5 CAPLUS
CN Benamide, N-ethyl-4-methyl-3-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861972-63-6 CAPLUS
CN Benamide, N-ethyl-4-methyl-3-[3-(4-piperidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)

10587989.trn


L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861972-64-7 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-5-(1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)



RN 861972-65-8 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 861972-66-9 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
2005:732641 Document No. 143:2119080 Preparation of fused heteroaryl derivatives as p38 kinase inhibitors. Patel, Vipulkumar Kantibhai; Swanson, Stephen (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 2005073217 A1 20050811, 54 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-GB266 20050127. PRIORITY: GB 2004-2138 20040130.


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by palladium catalyzed coupling of 6-bromo-5-fluoro-3-(4-pyridinyl)-1H-indazole (preparation given) with N-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. The activity of I was evaluated in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 µM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compds. comprising I are disclosed.


IT 862098-61-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)

RN 862098-61-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-[5-fluoro-3-(4-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




IT 862098-62-2P 862098-65-5P 862098-66-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)


L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 861972-67-0 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(4-piperidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 862098-62-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-[5-fluoro-3-(1-oxido-4-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-65-5 CAPLUS
CN Benzamide, N-ethyl-3-[5-fluoro-3-(6-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-66-6 CAPLUS
CN Benzamide, 3-[3-(6-chloro-3-pyridinyl)-5-fluoro-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)



10587989.trn

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 2005:729633 Document No. 143:2119060 Preparation of fused heteroaryl derivatives as p38 kinase inhibitors. Bamborough, Paul; Campos, Sebastien Andre; Patel, Vipulkumar Kantibhai; Swanson, Stephen; Walker, Ann Louise (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 2005073189 A1 20050811, 123 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-GB265 20050127. PRIORITY: GB 2004-2143 20040130.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and their pharmaceutically acceptable salts, are prepared and disclosed

as p38 kinase inhibitors. Thus, e.g., II was prepared by palladium catalyzed Suzuki coupling of 5-bromo-1-phenyl-1H-indazole (preparation given) with [5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]boronic acid.


The activity of I was evaluated in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 µM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compns. comprising I are disclosed.

IT 861904-32-7P 861904-72-5P 861904-73-6P
 861904-94-1P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
 RN 861904-32-7 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-72-5 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-73-6 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(4-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-94-1 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[3-(2-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 861904-25-8P 861904-26-9P 861904-27-0P
 861904-28-1P 861904-29-2P 861904-30-5P
 861904-31-6P 861904-33-8P 861904-34-9P
 861904-35-0P 861904-36-1P 861904-37-2P
 861904-38-3P 861904-39-4P 861904-40-7P
 861904-41-8P 861904-42-9P 861904-43-0P
 861904-44-1P 861904-45-2P 861904-50-9P
 861904-51-0P 861904-52-1P 861904-53-2P
 861904-54-3P 861904-56-5P 861904-57-6P
 861904-58-7P 861904-59-8P 861904-60-1P
 861904-62-3P 861904-64-5P 861904-66-7P
 861904-67-8P 861904-68-9P 861904-69-0P
 861904-75-8P 861904-76-9P 861904-77-0P
 861904-78-1P 861904-79-2P 861904-80-5P
 861904-81-6P 861904-82-7P 861904-83-8P
 861904-84-9P 861904-85-0P 861904-86-1P
 861904-87-2P 861904-88-3P 861904-89-4P
 861904-90-7P 861904-91-8P 861904-92-9P
 861904-93-0P 861904-95-2P 861904-96-3P
 861904-97-4P 861904-98-5P 861904-99-6P
 861905-00-2P 861905-01-3P 861905-02-4P
 861905-03-5P 861905-04-6P 861905-05-7P
 861905-06-8P 861905-07-9P 861905-08-0P
 861905-09-1P 861905-10-4P 861905-11-5P
 861905-12-6P 861905-13-7P 861905-15-9P
 861905-17-1P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
 RN 861904-25-8 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-phenyl-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-26-9 CAPLUS

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 861904-27-0 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-(4-fluoro-2-methylphenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 861904-28-1 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-[(4-fluorophenyl)methyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 861904-29-2 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-(trifluoromethyl)phenyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)

10587989.trn


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-30-5 CAPLUS
CN Benzamide,
N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-31-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(5-methyl-3-isoxazolyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-33-8 CAPLUS
CN Benzamide,
N-cyclopropyl-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2


CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 861904-37-2 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-38-3 CAPLUS
CN Benzamide, 3-fluoro-N,4-dimethyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-39-4 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-34-9 CAPLUS
CN Benzamide, N-cyclobutyl-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 861904-35-0 CAPLUS
CN Benzamide,
N-cyclobutyl-3-fluoro-4-methyl-5-[1-[4-(4-morpholinyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-36-1 CAPLUS
CN Formic acid, compd. with N-cyclobutyl-3-fluoro-4-methyl-5-[1-[4-(4-morpholinyl)phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 861904-35-0
CMF C28 H27 F N4 O2


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-40-7 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-propyl- (CA INDEX NAME)




RN 861904-41-8 CAPLUS
CN Benzamide, N-butyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-42-9 CAPLUS
CN Benzamide, N-cyclobutyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)

10587989.trn


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-43-0 CAPLUS
CN Benzamide, N-cyclopentyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-44-1 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-N-(1-methylethyl)-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-45-2 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-53-2 CAPLUS
CN Benzeneacetamide, 4-[5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-1-yl]-N-methyl- (CA INDEX NAME)



RN 861904-54-3 CAPLUS
CN Benzamide, 3-[1-(4-bromophenyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-56-5 CAPLUS
CN Formic acid, compd. with 3-[1-[4-[(cyclohexylmethyl)amino]phenyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide (1:1) (CA INDEX NAME)


CM 1

CRN 861904-55-4
CMF C31 H33 F N4 O


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-50-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-51-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(trifluoromethyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-52-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(methylsulfonyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2

CRN 64-18-6
CMF C H2 O2



RN 861904-57-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-[4-[[2-(dimethylamino)ethyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-58-7 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-[1-[4-[[2-(dimethylamino)ethyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide (2:1) (CA INDEX NAME)

CM 1

CRN 861904-57-6
CMF C28 H30 F N5 O

10587989.trn


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 861904-59-8 CAPLUS
CN Benzamide,
N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2H-pyran-4-yl)amino]phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-60-1 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2H-pyran-4-yl)amino]phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)

CM 1
CRN 861904-59-8
CMF C29 H29 F N4 O2

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
methoxyethyl)amino]phenyl]-1H-indazol-5-yl]-4-methylbenzamide (1:1) (CA INDEX NAME)

CM 1
CRN 861904-63-4
CMF C27 H27 F N4 O2




CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH


RN 861904-66-7 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-[1-[4-[[3-(dimethylamino)propyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide (2:1) (CA INDEX NAME)

CM 1
CRN 861904-65-6
CMF C29 H32 F N5 O



CM 2
CRN 64-18-6
CMF C H2 O2

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 861904-62-3 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[[[(tetrahydro-2H-furanyl)methyl]amino]phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)

CM 1
CRN 861905-17-1
CMF C29 H29 F N4 O2



CM 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 861904-64-5 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-fluoro-5-[1-[4-[(2-


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

O=CH-OH


RN 861904-67-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-[4-[(2,3-dihydroxypropyl)amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-68-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-[4-[(2,6-dimethyl-4-pyrimidinyl)-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-69-0 CAPLUS
CN Benzamide,
N-cyclopropyl-3-[1-(1,6-dihydro-6-oxo-4-pyrimidinyl)-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-75-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-2-pyridinyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)

10587989.trn


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-76-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[(1-oxido-3-pyridinyl)methyl]-1H-indazol-5-yl- (CA INDEX NAME)




RN 861904-77-0 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[(1-oxido-4-pyridinyl)methyl]-1H-indazol-5-yl- (CA INDEX NAME)




RN 861904-78-1 CAPLUS
CN Benzanide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-2-pyrimidinyl- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 861904-82-7 CAPLUS
CN Benzanide, N-(4-fluorophenyl)-4-methyl-3-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-83-8 CAPLUS
CN Benzanide, N-ethyl-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-84-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-79-2 CAPLUS
CN Benzanide, 3-fluoro-N-(4-fluorophenyl)-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-80-5 CAPLUS
CN Benzanide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-3-pyridazinyl- (CA INDEX NAME)




RN 861904-81-6 CAPLUS
CN Benzanide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-1H-pyrazol-3-yl- (CA INDEX NAME)

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 861904-85-0 CAPLUS
CN Benzanide, N-ethyl-3-[3-(4-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-86-1 CAPLUS
CN Benzanide, N-cyclopropyl-3-[3-(4-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-87-2 CAPLUS
CN Benzanide, N-ethyl-3-[3-(6-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-88-3 CAPLUS
CN Benzanide, 3-[3-(4-ethoxyphenyl)-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)

10587989.trn


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-89-4 CAPLUS
CN Benzanide, N-ethyl-3-methyl-3-[3-[4-(methylsulfonyl)phenyl]-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861904-90-7 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-4-methyl-5-[3-(4-methylphenyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861904-91-8 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-4-methyl-5-[3-[4-(trifluoromethyl)phenyl]-1H-indazol-6-yl]- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-96-3 CAPLUS
CN Benzanide, N-(1-ethyl-1H-pyrazol-5-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-97-4 CAPLUS
CN Benzanide, N-(1-ethyl-1H-pyrazol-5-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-98-5 CAPLUS
CN Benzanide, 3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-92-9 CAPLUS
CN Benzanide, 3-[3-(4-chlorophenyl)-1H-indazol-6-yl]-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-93-0 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(6-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-95-2 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(1-oxido-2-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861904-99-6 CAPLUS
CN Benzanide, 3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 861905-00-2 CAPLUS
CN Benzanide, N-ethyl-4-methyl-3-[3-[6-(4-morpholinyl)-3-pyridinyl]-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861905-01-3 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-4-methyl-5-[3-(2-pyrimidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)

10587989.trn


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861905-02-4 CAPLUS
CN Benzanide, N-ethyl-4-methyl-3-[3-(5-pyrimidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861905-03-5 CAPLUS
CN Benzanide, N-ethyl-4-methyl-3-[3-(2-pyrazinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861905-04-6 CAPLUS
CN Benzanide, N-ethyl-4-methyl-3-[3-(4-fluoro-2-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861905-08-0 CAPLUS
CN Benzanide, 3-[3-(3,5-dimethyl-4-isoxazolyl)-1H-indazol-6-yl]-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861905-09-1 CAPLUS
CN 3-Pyridinecarboxamide, N-ethyl-6-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-indazol-3-yl]- (CA INDEX NAME)




RN 861905-10-4 CAPLUS
CN Benzanide, N-(1,4-dimethyl-1H-pyrazol-5-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861905-05-7 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(2-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-06-8 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-5-[3-(4-fluoro-2-methylphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-07-9 CAPLUS
CN Benzanide, N-ethyl-3-fluoro-4-methyl-5-[3-(3-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861905-11-5 CAPLUS
CN Benzanide, N-(1,4-dimethyl-1H-pyrazol-5-yl)-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-12-6 CAPLUS
CN Benzanide, N-(3,5-dimethyl-4-isoxazolyl)-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-13-7 CAPLUS
CN Benzanide, 3-[3-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-6-yl]-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)

10587989.trn

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861905-15-9 CAPLUS
CN Formic acid, compd. with N-ethyl-3-fluoro-4-methyl-5-[3-(2-methyl-4-pyridinyl)-1H-indazol-6-yl]benzamide (1:1) (CA INDEX NAME)
CM 1
CRN 861905-14-8
CMF C23 H21 F N4 O




CM 2
CRN 64-18-6
CMF C H2 O2




RN 861905-17-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2-furanyl)methyl]amino]phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861905-37-5 CAPLUS
CN Benzamide, N-ethyl-3-(3-iodo-1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)




RN 861905-40-0 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-5-(3-iodo-1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)




RN 861905-69-3 CAPLUS
CN Benzamide, 3-(3-bromo-1H-indazol-6-yl)-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)


L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 651780-48-2P 651781-09-8P 861905-36-4P
861905-37-5P 861905-40-0P 861905-69-3P
861972-64-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
RN 651780-48-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methyl- (CA INDEX NAME)




RN 651781-09-8 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 861905-36-4 CAPLUS
CN Benzamide, N-ethyl-3-(1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 861972-64-7 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-5-(1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)



10587989.trn

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
2004:100989 Document No. 140:1461330 Preparation of fused heteroaryls, in particular benzisoxazoles and indazoles, for use as p38 kinase inhibitors in the treatment of rheumatoid arthritis. Angell, Richard Martyn; Baldwin, Ian Robert; Bamborough, Paul; Deboeck, Nigel Marc; Longstaff, Timothy; Swanson, Stephen (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 2004010995 A1 20040205, 135 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-GB3316 20030730. PRIORITY: GB 2002-17575 20020731.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein ACC = fused 5-membered heteroaryl; R1 = CH₃, Cl; R2 = NHCHO and derivs., CONH(CH₂)_qR₃; q = 0-2; R₃ = H, cyclo/alkyl, (un)substituted Ph, heteroaryl, etc.; X, Y = independently H, Me, halo] were prepared as p38 kinase inhibitors for treatment of rheumatoid arthritis. For example, II was prepared by Pd-cross coupling of 6-bromo-3-piperidin-4-yl-1,2-benzisoxazole and III (preparation given) at 80° for 18 h. In an vitro fluorescence anisotropy kinase binding assay, I gave IC₅₀ values < 10 μM for the inhibition of p38 kinase. Thus, I are useful in the treatment of conditions and diseases states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.

IT 651780-39-1P, N-Cyclopropyl-3-[[3-[(4-fluorophenyl)sulfonyl]-1-[[[2-(trimethylsilyl)ethyl]oxy]methyl]-1H-indazol-6-yl]-4-methylbenzamide 651780-45-9P, N-Cyclopropyl-3-fluoro-4-methyl-5-[3-(methylsulfonyl)-1-[[[2-(trimethylsilyl)ethyl]oxy]methyl]-1H-indazol-6-yl]benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused heteroaryls as p38 kinase inhibitors for treatment of rheumatoid arthritis)


RN 651780-39-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-[[3-[(4-fluorophenyl)sulfonyl]-1-[[[2-(trimethylsilyl)ethoxy]methyl]-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


CN 1H-Indazole-1-acetic acid, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-, methyl ester (CA INDEX NAME)



RN 651780-50-6 CAPLUS
CN 1H-Indazole-1-acetic acid, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-, methyl ester (CA INDEX NAME)




RN 651781-74-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 651780-03-9P 651780-68-6P, N-Cyclopropyl-4-methyl-3-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide 651780-69-7P, N-Cyclopropyl-3-[1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651780-70-0P, 3-[1-[(3-Cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide 651780-71-1P, N-Cyclopropyl-3-[1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651780-72-2P, N-Cyclopropyl-4-methyl-3-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide 651780-73-3P, N-Cyclopropyl-3-[1-[(2,3-dihydro-1-benzofuran-5-yl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651780-74-4P, N-Cyclopropyl-3-[1-[(3-methoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651780-75-5P, 3-[1-(Benzylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide 651780-76-6P, N-Cyclopropyl-3-[1-[[5-(isoxazol-3-yl)thien-2-yl]sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651780-77-7P, 3-[1-[(4-Acetylphenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651780-45-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[3-(methylsulfonyl)-1-[[[2-(trimethylsilyl)ethoxy]methyl]-1H-indazol-6-yl]- (CA INDEX NAME)




IT 651780-47-1P, N-Cyclopropyl-3-(1H-indazol-5-yl)-4-methylbenzamide 651780-49-3P, Methyl

[5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]acetate 651780-50-6P, Methyl [5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-1-yl]acetate 651781-74-7P, 1,1-Dimethylethyl

4-[5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]-1-piperidinecarboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(p38 kinase inhibitor; preparation of fused heteroaryls as p38 kinase inhibitors for treatment of rheumatoid arthritis)

RN 651780-47-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-(1H-indazol-5-yl)-4-methyl- (CA INDEX NAME)



RN 651780-49-3 CAPLUS

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

methylbenzamide 651780-78-8P, Methyl 4-[[[5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]sulfonyl]methyl]benzoate 651780-79-9P, N-Cyclopropyl-3-[1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651780-80-2P, N-Cyclopropyl-4-methyl-3-[1-[(4-(trifluoromethyl)phenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651780-81-3P, N-Cyclopropyl-3-[1-[(4-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-09-8P, 1,1-Dimethylethyl 5-[5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazole-1-carboxylate 651781-10-1P, N-Cyclopropyl-4-methyl-3-[1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-11-2P, N-Cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide 651781-12-3P, N-Cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide 651781-13-4P, Methyl 5-[5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]sulfonyl]-2-furancarboxylate 651781-14-5P,

3-[1-[(2,1,3-Benzoxadiazol-4-yl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide 651781-15-6P, N-Cyclopropyl-3-[1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-16-7P, N-Cyclopropyl-4-methyl-3-[1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-17-8P, N-Cyclopropyl-4-methyl-3-[1-[(2-thienyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-18-9P,

N-Cyclopropyl-3-[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-19-0P, N-Cyclopropyl-4-methyl-3-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide 651781-20-3P, N-Cyclopropyl-4-methyl-3-[1-[(2-nitrophenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-21-4P,

N-Cyclopropyl-4-methyl-3-[1-[(2,2,2-trifluoroethyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-22-5P, 3-[1-[(2-Cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide 651781-23-6P,

N-Cyclopropyl-4-methyl-3-[1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-24-7P, N-Cyclopropyl-4-methyl-3-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-25-8P, N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(2-thienyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-26-9P, N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(3-thienyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-27-0P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-28-1P, N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-methoxyphenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-30-5P, N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-(1-methylethyl)phenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-32-7P,

3-[1-[(4-Chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide 651781-34-9P, N-Cyclopropyl-3-[1-[(2,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-36-1P,

10587989.trn

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

3-[1-[(3-Chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide 651781-38-3P,

N-Cyclopropyl-3-fluoro-5-[1-[(5-fluoro-2-methylphenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-40-7P,

N-Cyclopropyl-3-fluoro-5-[1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-42-9P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(3-(methyloxy)phenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-43-0P,

N-Cyclopropyl-3-[1-[(3,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-45-2P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(3-methylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-47-4P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-49-6P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide 651781-50-9P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide 651781-51-0P,

3-[1-(Butylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide 651781-52-1P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(octylsulfonyl)-1H-indazol-5-yl]benzamide 651781-53-2P,

N-Cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-54-3P,

3-[1-[(5-Chloro-2-thienyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide 651781-55-4P,

N-Cyclopropyl-3-[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-56-5P,

N-Cyclopropyl-3-[1-[(1,2-dimethyl-1H-indazol-4-yl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-57-6P,

N-Cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-58-7P,

3-[1-[(2-Chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide 651781-59-8P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(2-methylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-60-1P,

N-Cyclopropyl-3-[1-[(4-ethylphenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-61-2P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-propylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-62-3P,

N-Cyclopropyl-3-[1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-63-4P,

3-[1-[(4-Butylphenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide 651781-64-5P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide 651781-65-6P,

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

[(methylamino)carbonyl]phenyl[methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-92-9P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[2-oxo-2-(propylamino)ethyl]-1H-indazol-5-yl]benzamide 651781-93-0P,

N-Cyclopropyl-3-[1-[2-[4-(cyclopropylmethyl)amino]-2-oxoethyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-94-1P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-95-2P,

N-Cyclopropyl-4-methyl-3-[1-[2-[(1-methylethyl)amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-96-3P,


N-Cyclopropyl-3-[1-[2-[(2,2-dimethylpropyl)amino]-2-oxoethyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-97-4P,

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; prepn. of fused heteroaryls as p38 kinase inhibitors for treatment of rheumatoid arthritis)

RN 651780-03-9 CAPLUS


CN Benzamide, N-cyclopropyl-3-(1H-indazol-6-yl)-4-methyl- (CA INDEX NAME)



RN 651780-68-6 CAPLUS

CN Benzamide,

N-cyclopropyl-4-methyl-3-[1-(phenylsulfonyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 651780-69-7 CAPLUS

CN Benzamide,

N-cyclopropyl-3-[1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

yl]benzamide 651781-65-6P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(phenylmethyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-66-7P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(E)-2-phenylethenyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-67-8P,

N-Cyclopropyl-3-[1-[(2,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-68-9P,

N-Cyclopropyl-3-fluoro-5-[1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-69-0P,

3-[1-[(4-Cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide 651781-70-3P,

N-Cyclopropyl-3-[1-[(2,3-dihydro-1-benzofuran-5-yl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide 651781-73-6P,

N-Cyclopropyl-3-[1-(cyclopropylmethyl)-1H-indazol-5-yl]-4-methylbenzamide 651781-75-8P,

N-Cyclopropyl-4-methyl-3-[1-[(4-piperidinyl)-1H-indazol-5-yl]benzamide hydrochloride 651781-76-9P,

N-Cyclopropyl-3-[3-[(4-fluorophenyl)sulfonyl]-1H-indazol-6-yl]-4-methylbenzamide 651781-77-0P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[3-(methylsulfonyl)-1H-indazol-6-yl]benzamide 651781-78-1P,

N-Cyclopropyl-3-fluoro-4-methyl-5-(3-methyl-1H-indazol-5-yl)benzamide 651781-79-2P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[3-methyl-1-[(2-thienyl)sulfonyl]-1H-indazol-5-yl]benzamide 651781-80-5P,

N-Cyclopropyl-4-methyl-3-[1-[2-[[[4-(methyloxy)phenyl]methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-81-6P,

N-Cyclopropyl-4-methyl-3-[1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-1H-indazol-5-yl]benzamide 651781-82-7P,

N-Cyclopropyl-4-methyl-3-[1-[2-[[[4-methylphenyl]methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-83-8P,

N-Cyclopropyl-4-methyl-3-[1-[2-[[[4-(methylamino)carbonyl]phenyl]methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-84-9P,

N-Cyclopropyl-4-methyl-3-[1-[2-oxo-2-(propylamino)ethyl]-1H-indazol-5-yl]benzamide 651781-85-0P,

N-Cyclopropyl-3-[1-[2-[(cyclopropylmethyl)amino]-2-oxoethyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-86-1P,

N-Cyclopropyl-3-[1-[2-[(2,2-dimethylpropyl)amino]-2-oxoethyl]-1H-indazol-5-yl]-4-methylbenzamide 651781-87-2P,

N-Cyclopropyl-4-methyl-3-[1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-88-3P,


N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-1H-indazol-5-yl]benzamide 651781-89-4P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[2-[[[4-methylphenyl]methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-90-7P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[2-[[[4-(methyloxy)phenyl]methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide 651781-91-8P,

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[2-[[[4-


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651780-70-0 CAPLUS

CN Benzamide,


3-[1-[(3-cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 651780-71-1 CAPLUS

CN Benzamide,

N-cyclopropyl-3-[1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651780-72-2 CAPLUS

CN Benzamide,


N-cyclopropyl-4-methyl-3-[1-(methylsulfonyl)-1H-indazol-5-yl]- (CA INDEX NAME)

10587989.trn


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651780-73-3 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651780-74-4 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(3-methoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651780-75-5 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(phenylmethyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651780-79-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651780-80-2 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(4-(trifluoromethyl)phenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651780-81-3 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(4-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651780-76-6 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(5-(3-isoxazolyl)-2-thienyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651780-77-7 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(4-acetylphenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)




RN 651780-78-8 CAPLUS
CN Benzoic acid, 4-[[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl)sulfonyl]-1H-indazol-5-yl]methyl-, methyl ester (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-09-8 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 5-[[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1,1-dimethylethyl ester (CA INDEX NAME)




RN 651781-10-1 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651781-11-2 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(ethylsulfonyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)

10587989.trn


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-12-3 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651781-13-4 CAPLUS
CN 2-Furancarboxylic acid, 5-[[5-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]sulfonyl]-, methyl ester (CA INDEX NAME)




RN 651781-14-5 CAPLUS
CN Benzanide, 3-[1-(2,1,3-benzoxadiazol-4-ylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-15-6 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651781-16-7 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-[1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 651781-17-8 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 651781-18-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 651781-19-0 CAPLUS
CN Benzanide, N-cyclopropyl-3-[1-(propylsulfonyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651781-20-3 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-[1-[(2-nitrophenyl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)




L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 651781-21-4 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-[1-[(2,2,2-trifluoroethyl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 651781-22-5 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-[1-[(2-cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)




RN 651781-23-6 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-[1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 651781-24-7 CAPLUS
CN Benzanide, N-cyclopropyl-4-methyl-3-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)

10587989.trn


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-25-8 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 651781-26-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 651781-27-0 CAPLUS
CN Benzanide,
N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-34-9 CAPLUS
CN Benzanide,
N-cyclopropyl-3-[1-[(2,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 651781-36-1 CAPLUS
CN Benzanide,
3-[1-[(3-chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 651781-38-3 CAPLUS
CN Benzanide,
N-cyclopropyl-3-fluoro-5-[1-[(5-fluoro-2-methylphenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-28-1 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-5-[1-[(4-methoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651781-30-5 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-methylethylphenyl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 651781-32-7 CAPLUS
CN Benzanide,
3-[1-[(4-chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-40-7 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-5-[1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)






RN 651781-42-9 CAPLUS
CN Benzanide, N-cyclopropyl-3-fluoro-5-[1-[(3-methoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)






RN 651781-43-0 CAPLUS
CN Benzanide,
N-cyclopropyl-3-[1-[(3,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)






L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
5-y1]- (CA INDEX NAME)



L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




10587989.trn


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-59-8 CAPLUS
CN Benzamide,
N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(2-methylphenyl)sulfonyl]-
1H-indazol-5-yl]- (CA INDEX NAME)




RN 651781-60-1 CAPLUS
CN Benzamide,
N-cyclopropyl-3-[1-[(4-ethylphenyl)sulfonyl]-1H-indazol-5-yl]-5-
fluoro-4-methyl- (CA INDEX NAME)




RN 651781-61-2 CAPLUS
CN Benzamide,
N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-propylphenyl)sulfonyl]-
1H-indazol-5-yl]- (CA INDEX NAME)

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 651781-65-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(phenylmethyl)sulfonyl]-
1H-indazol-5-yl]- (CA INDEX NAME)




RN 651781-66-7 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1E)-2-
phenylethenyl)sulfonyl]-1H-indazol-5-yl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 651781-67-8 CAPLUS
CN Benzamide,
N-cyclopropyl-3-[1-[(2,5-difluorophenyl)sulfonyl]-1H-indazol-5-
yl]-5-fluoro-4-methyl- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-62-3 CAPLUS
CN Benzamide,
N-cyclopropyl-3-[1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-
yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 651781-63-4 CAPLUS
CN Benzamide,
3-[1-[(4-butylphenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-
fluoro-4-methyl- (CA INDEX NAME)




RN 651781-64-5 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-
indazol-5-yl]- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-68-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-[(2-fluorophenyl)sulfonyl]-1H-
indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651781-69-0 CAPLUS
CN Benzamide,
3-[1-[(4-cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-
fluoro-4-methyl- (CA INDEX NAME)




RN 651781-70-3 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-1H-
indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)

10587989.trn


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-73-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-(cyclopropylmethyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 651781-75-8 CAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[1-(4-piperidinyl)-1H-indazol-5-yl]-, hydrochloride (1:1) (CA INDEX NAME)




• HCl

RN 651781-76-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-[3-[(4-fluorophenyl)sulfonyl]-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)


L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 651781-80-5 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 651781-81-6 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 651781-82-7 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-77-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[3-(methylsulfonyl)-1H-indazol-6-yl]- (CA INDEX NAME)



RN 651781-78-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-(3-methyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 651781-79-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[3-methyl-1-(2-thienylsulfonyl)-1H-indazol-5-yl]- (CA INDEX NAME)

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 651781-83-8 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-[4-[(methylamino)carbonyl]phenyl]methyl- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—NHMe

RN 651781-84-9 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-propyl- (CA INDEX NAME)




RN 651781-85-0 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




10587989.trn

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 651781-86-1 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 651781-87-2 CAPLUS
CN Benzamide, N-cyclopropyl-4-methyl-3-[1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 651781-88-3 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 651781-89-4 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-B

—NHMe

RN 651781-92-9 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-propyl- (CA INDEX NAME)




RN 651781-93-0 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 651781-94-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl]- (CA INDEX NAME)

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 651781-90-7 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 651781-91-8 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-[(4-[(methylamino)carbonyl]phenyl)methyl]- (CA INDEX NAME)


PAGE 1-A




L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 651781-95-2 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 651781-96-3 CAPLUS
CN 1H-Indazole-1-acetamide, 5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)




IT 651780-48-2, N-Cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused heteroaryls as p38 kinase inhibitors for treatment of rheumatoid arthritis)

RN 651780-48-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methyl- (CA INDEX NAME)

10587989.trn

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10587989.trn

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

L15 61 S L6
L16 6 S L15 AND P38
L17 5 S L16 NOT L8
L18 1 S L16 AND L8

=> s l15 and kinase

379490 KINASE
69447 KINASES
391032 KINASE
(KINASE OR KINASES)

L19 36 L15 AND KINASE

=> s l19 and pd<=2004

25095048 PD<=2004
(PD<=20049999)

L20 4 L19 AND PD<=2004

=> s l19 and prd<=2004

4643961 PRD<=2004
(PRD<=20049999)

L21 13 L19 AND PRD<=2004

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

10587989.trn

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010
L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010
L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010
L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS


FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010
L15 61 S L6
L16 6 S L15 AND P38
L17 5 S L16 NOT L8
L18 1 S L16 AND L8
L19 36 S L15 AND KINASE
L20 4 S L19 AND PD<=2004
L21 13 S L19 AND PRD<=2004

=> s l21 not l16
L22 8 L21 NOT L16

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y


10587989.trn

L22 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 2006:13000 Document No. 144:882830 Preparation of indazole carboxamides as
 IKK β kinase inhibitors for the treatment of a variety of
 disorders. Kerns, Jeffrey, K.; Edwards, Christine (Smithkline Beecham
 Corporation, USA). PCT Int. Appl. WO 2006002434 A2 20060105, 113 pp.
 DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,
 BY,
 BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
 GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NG, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF,
 BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT,
 LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN:
 PIXXD2. APPLICATION: WO 2005-US22870 20050624. PRIORITY: US
 2004-582655P
 20040624.
 GI




AB Title compds. I [Z = (un)substituted (hetero)aryl; R1 = H, halo, WK; W =
 bond, alkylene; X = (un)substituted (hetero)aryl, heterocycloalkyl,
 cycloalkyl, etc.] are prepared For instance,
 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-phenyl-1H-indazole-7-carboxamide is
 prepared in 6 steps from 1-(tert-butoxycarbonyl)piperidine-4-carboxylic
 acid, 5-bromo-2-fluorobenzonitrile, hydrazine and ethanesulfonyl
 chloride.
 Compds. of the invention are inhibitors of IKK2 kinase with a
 pIC50 > 5.0. I are useful in the treatment of rheumatoid arthritis,
 asthma, and COPD (chronic obstructive pulmonary disease).
 IT 872351-22-9P, 1,1-Dimethylethyl
 4-[5-[3-(acetylamino)phenyl]-7-(aminocarbonyl)-1H-indazol-3-yl]-1-
 piperidinecarboxylate 872351-24-1P, 1,1-Dimethylethyl
 4-[5-[4-(acetylamino)phenyl]-7-(aminocarbonyl)-1H-indazol-3-yl]-1-
 piperidinecarboxylate
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indazole carboxamides as IKK β kinase
 inhibitors for treatment of variety of disorders)
 RN 872351-22-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[3-(acetylamino)phenyl]-7-
 (aminocarbonyl)-1H-indazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX
 NAME)

L22 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 (Uses)
 (prepn. of indazole carboxamides as IKK β kinase
 inhibitors for treatment of variety of disorders)
 RN 872350-64-6 CAPLUS
 CN 1H-Indazole-7-carboxamide, 5-[3-(acetylamino)phenyl]-3-[1-[(1,2-dimethyl-
 1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 872350-66-8 CAPLUS
 CN 1H-Indazole-7-carboxamide, 5-[4-(acetylamino)phenyl]-3-[1-[(1,2-dimethyl-
 1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 872351-23-0 CAPLUS
 CN 1H-Indazole-7-carboxamide, 5-[3-(acetylamino)phenyl]-3-(4-piperidinyl)-,
 hydrochloride (1:1) (CA INDEX NAME)

L22 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 872351-24-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[4-(acetylamino)phenyl]-7-
 (aminocarbonyl)-1H-indazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX
 NAME)




IT 872350-64-6P, 5-[3-(Acetylamino)phenyl]-3-[1-[(1,2-dimethyl-1H-
 imidazol-4-yl)sulfonyl]-4-piperidinyl]-1H-indazole-7-carboxamide
 872350-66-8P, 5-[4-(Acetylamino)phenyl]-3-[1-[(1,2-dimethyl-1H-
 imidazol-4-yl)sulfonyl]-4-piperidinyl]-1H-indazole-7-carboxamide
 872351-23-0P, 5-[3-(Acetylamino)phenyl]-3-(4-piperidinyl)-1H-
 indazole-7-carboxamide hydrochloride 872351-25-2P,
 5-[4-(Acetylamino)phenyl]-3-(4-piperidinyl)-1H-indazole-7-carboxamide
 hydrochloride
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L22 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 872351-25-2 CAPLUS
 CN 1H-Indazole-7-carboxamide, 5-[4-(acetylamino)phenyl]-3-(4-piperidinyl)-,
 hydrochloride (1:1) (CA INDEX NAME)




● HCl


IT 872350-65-7, 5-[3-(Acetylamino)phenyl]-3-(4-piperidinyl)-1H-
 indazole-7-carboxamide 872350-67-9,
 5-[4-(Acetylamino)phenyl]-3-(4-piperidinyl)-1H-indazole-7-carboxamide
 RI: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of indazole carboxamides as IKK β kinase
 inhibitors for treatment of variety of disorders)
 RN 872350-65-7 CAPLUS
 CN 1H-Indazole-7-carboxamide, 5-[3-(acetylamino)phenyl]-3-(4-piperidinyl)-
 (CA INDEX NAME)

10587989.trn


L22 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 872350-67-9 CAPLUS
CN 1H-Indazole-7-carboxamide, 5-[4-(acetylamino)phenyl]-3-(4-piperidinyl)-
(CA INDEX NAME)



L22 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 871708-82-6 CAPLUS
CN Acetamide, N-[3-(3-amino-1H-indazol-5-yl)phenyl]- (CA INDEX NAME)



L22 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
2005:1350605 Document No. 144:698370 Preparation of 3-aminoindazoles as
serum and glucocorticoid-regulated kinase (SGK) inhibitors.
Dorsch, Dieter; Burgdorf, Lars Thore; Gericke, Rolf; Beier, Norbert;
Mederski, Werner; Lang, Florian (Merck Patent GmbH, Germany). PCT Int.
Appl. WO 2005123688 A2 20051229, 136 pp. DESIGNATED STATES: W: AE, AG,
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE,
SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2005-EP3513
20050404. PRIORITY: DE 2004-102004028862 20040615.



GI



AB Title compds. I [Y = W-R1; X = H, halo, NO2, etc.; R1 = carbocycle,
heterocycle, etc.; W = [C(R2)2]n-[C(R2)2]nCONR2[C(R2)2]n, etc.; R2 = H,
A,
etc.; A = alkyl, alkylene, etc.] and their pharmaceutically acceptable
salts and formulations were prepared For example, coupling of carboxylic
acid II and 3-chlorobenzylamine afforded aminoindazole III. Compds. I
are
claimed to be useful as glucocorticoid-regulated kinase (SGK)
inhibitors (no data provided).
IT 871708-22-4P 871708-82-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 3-aminoindazoles as serum and glucocorticoid-regulated
kinase (SGK) inhibitors)
RN 871708-22-4 CAPLUS
CN Benzoic acid, 3-(3-amino-1H-indazol-5-yl)-, hydrazide (CA INDEX NAME)

L22 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
2005:1290082 Document No. 144:363350 Preparation of substituted indazoles
as
kinase inhibitors, and their compositions and use for treatment of
cancer. Halley, Franck; Tabart, Michel; Bouchard, Herve; Souaille,
Catherine; Le Brun, Alain; Viviani, Fabrice; Gauzy, Laurence; Desmazeau,
Pascal (Aventis Pharma SA, Fr.). Fr. Demande FR 2871158 A1 20051209, 35
pp. (French). CODEN: FRXXBL. APPLICATION: FR 2004-6042 20040604.


GI




AB Title compds. I [A = H, (un)substituted hetero/aryl; Ar = (un)substituted
hetero/aryl; L = a bond, CO, NH, NH-CO-NH, etc.; M = a bond, CO, NH-SO2,
NH-CO, etc.; R3 = independently H, (un)substituted hetero/aryl,
cycloalkyl, etc.; R4, R5, R7 = independently H, halo, CN, (un)substituted
alk(en/yn)yl, etc.; and their racemates, stereoisomers, salts and
pharmaceutically acceptable salts] were prepared as kinase
inhibitors for treatment especially of cancer. For example, reacting
6-(4-aminophenyl)-7-fluoro-3-[[[(thiophen-3-yl)carbonyl]amino]-1H-
indazole]•HCl (preparation given) with 2-fluoro-5-trifluoromethylphenyl
isocyanate in THF in the presence of TEA at 20° for 12 h gave
indazole II. Indazole II inhibited KDR and Tie2 kinases with an
IC50 of 6 nM and 9 nM. Thus, I and their pharmaceutical compns. are
useful as antitumor agents (no data).
IT 870772-80-8P, 6-[4-[(tert-Butoxycarbonyl)amino]phenyl]-3-
[[[(thiophen-3-yl)carbonyl]amino]-7-fluoro-1H-indazole
870772-81-9P, 3-Amino-7-fluoro-6-[4-[(tert-
butoxycarbonyl)amino]phenyl]-1H-indazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

10587989.trn

L22 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 (Reactant or reagent)
 (intermediate; prepn. of indazoles as kinase inhibitors for
 treating cancer)
 RN 870772-80-8 CAPLUS
 CN Carbanic acid, [4-[7-fluoro-3-[(3-thienylcarbonyl)amino]-1H-indazol-6-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 870772-81-9 CAPLUS
 CN Carbanic acid, [4-(3-amino-7-fluoro-1H-indazol-6-yl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 870772-74-0P, 1-[4-[7-Fluoro-3-[[[(thiophen-3-yl)carbonyl]amino]-1H-indazol-6-yl]phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Kinase inhibitor; preparation of indazoles as kinase inhibitors for treating cancer)

RN 870772-74-0 CAPLUS
 CN 3-Thiophenecarboxamide, N-[7-fluoro-6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-1H-indazol-3-yl]- (CA INDEX NAME)


L22 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 870772-77-3 CAPLUS
 CN 3-Thiophenecarboxamide, N-[4,5,7-trifluoro-6-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-1H-indazol-3-yl]- (CA INDEX NAME)




RN 870772-84-2 CAPLUS
 CN Urea, N-[4-(3-amino-7-fluoro-1H-indazol-6-yl)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


L22 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 870772-66-0P, 1-[4-(3-Amino-1H-indazol-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea 870772-73-9P, 1-[4-(3-Amino-7-fluoro-1H-indazol-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea 870772-77-3P,

1-(2-Fluoro-5-trifluoromethylphenyl)-3-[4-[4,5,7-trifluoro-3-[[[(thiophen-3-yl)carbonyl]amino]-1H-indazol-6-yl]phenyl]urea 870772-84-2P, 1-[4-(3-Amino-7-fluoro-1H-indazol-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea monohydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Kinase inhibitor; preparation of indazoles as kinase inhibitors for treating cancer)


RN 870772-66-0 CAPLUS
 CN Urea, N-[4-(3-amino-1H-indazol-6-yl)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 870772-73-9 CAPLUS
 CN Urea, N-[4-(3-amino-7-fluoro-1H-indazol-6-yl)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L22 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 2005:823509 Document No. 143:2295720 Preparation of benzamides for treating a disorder mediated by inappropriate ROCK-1 activity. Drewry, David Kendall; Jung, David Kendall; Linn, James Andrew; Hunter, Robert Neil, III; Lee, Dennis; Stavenger, Robert A.; Sehon, Clark (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 2005074643 A2 20050818, 47 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,

BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SM, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-US3479 20050128. PRIORITY: US 2004-540621P 20040130. GI




AB The title compds. I [R1 = H, alkyl or as indicated by the dotted line is fused to the Ph forming a 5-6 membered ring, optionally containing a double bond; n = 0-4; R2 = (un)substituted aryl, etc.; or when n = 0 then NR1R2 =

5-6 membered monocyclic heterocyclic ring or 9-10 membered bicyclic heterocyclic ring; X = indazolyl, pyrazolyl, (un)substituted pyridyl, pyrimidinyl, useful for treating disorders mediated by inappropriate ROCK-1 activity, were prepared E.g., a 3-step synthesis of II, starting from Me 4-bromobenzoate and 4-pyridylboronic acid, was given. All exemplified compds. I showed inhibitory activity vs. Rock-1 with a pIC50 of 5.0 or greater. The pharmaceutical composition comprising the compound I is disclosed.

IT 862723-06-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzamides for treating a disorder mediated by inappropriate ROCK-1 activity)
 RN 862723-06-6 CAPLUS
 CN Benzamide, 4-(1H-indazol-5-yl)-N-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)


10587989.trn

L22 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L22 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
2005:99335 Document No. 142:1980670 Preparation of
pyrazolo[3,4-c]isoquinoline derivatives as anaplastic lymphoma
kinase modulators. Anand, Neel Kumar; Blazey, Charles M.; Bowles,
Owen Joseph; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffrey Kimo;
Dubenko, Larisa; Kennedy, Abigail R.; Khoury, Richard G.; Kim, Angie I.;
Manalo, Jean-Claire L.; Peto, Csaba J.; Rice, Kenneth D.; Tsang, Tsz H.
(Exelixis, Inc., USA). PCT Int. Appl. WO 2005009389 A2 20050203, 239 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,

BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG,
CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR,
NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION:
WO 2004-US23762 20040723. PRIORITY: US 2003-489658P 20030723.
GI




AB The title compds. I [wherein A = (hetero)cycle; R1-R3 = independently H,
halo, CN, etc.; X1 and X2 = independently N or (un)substituted CH; X3 =
O,
S, or (un)substituted NH; n = 1-5; Y = N or (un)substituted CH] or
pharmaceutically acceptable salts, stereoisomers, prodrugs, or
metabolites
thereof are prepared as inhibitors of anaplastic lymphoma kinase
(ALK). For example, the compound II was prepared in a multi-step
synthesis.
Some of compds. I inhibited ALK with IC50 of ≤ 99 nM. I are useful
for the treatment of diseases mediated by ALK, including diseases such as
cancer, immunol. disorders, cardiovascular diseases, and other
degenerative disorders (no data). Formulations containing I as an active
ingredient were also described.
IT 838857-87-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of pyrazolo[3,4-c]isoquinoline derivs. as
anaplastic lymphoma kinase modulators)
RN 838857-87-7 CAPLUS
CN Acetamide, N-[4-(6-fluoro-2,3-dihydro-11-methyl-9H-1,4-dioxino[2,3-

L22 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
f]pyrazolo[3,4-c]isoquinolin-7-yl]phenyl]- (CA INDEX NAME)




L22 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
2004:1154680 Document No. 142:938140 Preparation of (indazolylphenyl),
(benzisoxazolylphenyl), (benzisothiazolylphenyl) ureas and related
compounds as protein tyrosine kinase inhibitors for treatment of
cancer. Dai, Yujia; Davidisen, Steven K.; Ericsson, Anna M.; Hartandi,
Kresna; Ji, Zhigui; Michaelides, Michael R. (Abbott Laboratories, USA).
PCT Int. Appl. WO 2004113304 A1 20041229, 224 pp. DESIGNATED STATES: W:
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO,
CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
DM, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US16166
20040521. PRIORITY: US 2003-443254 20030522; US 2004-842292 20040510.
GI




AB The present invention also discloses methods of making the compds.,
compns. containing the compds., and methods of treatment using the
compds.
Title compds. I [wherein A = Ph or Ph fused to a 5- or 6-membered ring
containing 1-2 N atoms; X = O, NR9, S; R1, R2 = independently H,
alkoxy(alkoxy), alkoxyalkyl, aryloxy(alkyl), halo(alkoxy), haloalkyl,
heterocyclalkenyl, heterocyclalkoxy, heterocycl(oxy)alkyl,
hydroxy(alkoxy), hydroxyalkyl, (un)substituted aminoalkoxy, ,
aminoalkenyl, aminoalkyl, carbamoylalkenyl, carbamoylalkyl; R3-R5 =
independently H, alkoxy, alkyl, halo(alkoxy), haloalkyl, LR6; with the
 proviso that at least 2 of R3-R5 ≠ LR6; L = (CH2)nNR7CONR8(CH2)n,
CH2CONR7; R6 = (hetero)aryl; R7, R8 = independently H, alkyl; R9 = H,
alkenyl, (alkoxy)alkyl, heterocyclalkyl, hydroxyalkyl, (un)substituted
aminoalkyl; m, n = independently 0, 1; and therapeutically acceptable
salts thereof] were prepared as protein tyrosine kinase
inhibitors. For example, the (indazolylphenyl)urea II was synthesized in
three steps starting from 2-fluoro-6-iodobenzonitrile, hydrazine hydrate,
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, and
1-isocyanato-3-methylbenzene. Compds. of the invention inhibited human
KDR with IC50 values ranging between about 0.003μM and about 40 μM.
Thus, I and their pharmaceutical compns. are useful in the treatment of

10587989.trn

L22 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 KDR mediated diseases, such as cancer (no data).
 IT 796970-44-0P, N-[4-(3-Amino-4-bromo-1H-indazol-6-yl)phenyl]-N'-(3-methylphenyl)urea 819056-41-2P,
 1-[4-(3-Amino-1H-indazol-6-yl)phenyl]-3-(3-methylphenyl)urea
 819056-42-3P, 3-Amino-N-(3-methylphenyl)-6-[4-[[[(3-methylphenyl)amino]carbonyl]amino]phenyl]-1H-indazole-1-carboxamide
 819058-93-0P, 1-[4-(3-Amino-1H-indazol-6-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea 819059-04-6P,
 1-[4-(3-Amino-1H-indazol-6-yl)phenyl]-3-phenylurea 819059-05-7P,
 1-[4-(3-Amino-1H-indazol-6-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (KDR inhibitor; preparation of (indazolylphenyl), (benzisoxazolylphenyl), (benzisothiazolylphenyl) ureas and related compds. as KDR kinase inhibitors for treatment of cancer)
 RN 796970-44-0 CAPLUS
 CN Urea, N-[4-(3-amino-1H-indazol-6-yl)phenyl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 819056-41-2 CAPLUS
 CN Urea, N-[4-(3-amino-1H-indazol-6-yl)phenyl]-N'-(3-methylphenyl)- (CA INDEX NAME)




RN 819056-42-3 CAPLUS
 CN 1H-Indazole-1-carboxamide, 3-amino-N-(3-methylphenyl)-6-[4-[[[(3-methylphenyl)amino]carbonyl]amino]phenyl]- (CA INDEX NAME)


L22 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L22 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 819058-93-0 CAPLUS
 CN Urea,
 N-[4-(3-amino-1H-indazol-6-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)- (CA INDEX NAME)




RN 819059-04-6 CAPLUS
 CN Urea, N-[4-(3-amino-1H-indazol-6-yl)phenyl]-N'-phenyl- (CA INDEX NAME)



RN 819059-05-7 CAPLUS
 CN Urea,
 N-[4-(3-amino-1H-indazol-6-yl)phenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)

L22 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 2004:1019784 Document No. 142:65280 Preparation of (indazolylphenyl) and (benzisoxazolylphenyl) ureas and related compounds as protein tyrosine kinase inhibitors for treatment of cancer. Dai, Yujia; Davidsen, Steven K.; Ericsson, Anna M.; Hartandi, Kresna; Ji, Zhigui; Michaelides, Michael R. (Abbott Laboratories, USA). U.S. Pat. Appl. Publ. US 20040235892 A1 20041125, 49 pp. (English). CODEN: USXXCO. APPLICATION: US 2003-443254 20030522.


GI




AB Title compds. I [wherein A = Ph or Ph fused to a 5- or 6-membered ring containing 1-2 N atoms; X = O, NR 9; R1, R2 = independently H, alkoxy (alkoxy), alkoxyalkyl, aryloxy (alkyl), halo (alkoxy), haloalkyl, heterocyclalkenyl, heterocyclalkoxy, heterocycl (oxy)alkyl, hydroxy (alkoxy), hydroxyalkyl, (un)substituted aminoalkoxy, , aminoalkenyl, aminoalkyl, carbamoylalkenyl, carbamoylalkyl; R3-R5 = independently H, alkoxy, alkyl, halo (alkoxy), haloalkyl, LR6; with the proviso that at least 2 of R3-R5 ≠ LR6; L = (CH2)mNR7CONR8(CH2)n, CH2CONR7; R6 = (hetero)aryl; R7, R8 = independently H, alkyl; R9 = H, alkenyl, (alkoxy)alkyl, heterocyclalkyl, hydroxyalkyl, (un)substituted aminoalkyl; m, n = independently 0, 1; and therapeutically acceptable salts thereof] were prepared as protein tyrosine kinase inhibitors. For example, the (indazolylphenyl)urea II was synthesized in three steps starting from 2-fluoro-6-iodobenzonitrile, hydrazine hydrate, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, and 1-isocyanato-3-methylbenzene. Compds. of the invention inhibited human KDR with IC50 values ranging between about 0.003μM and about 40 μM. Thus, I and their pharmaceutical compns. are useful in the treatment of KDR mediated diseases, such as cancer (no data).
 IT 796970-44-0P, N-[4-(3-Amino-4-bromo-1H-indazol-6-yl)phenyl]-N'-(3-methylphenyl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10587989.trn

L22 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(KDR inhibitor; prepn. of (indazolylphenyl) and (benzoxazolylphenyl) ureas and related compds. as KDR kinase inhibitors for treatment of cancer)
RN 796970-44-0 CAPLUS
CN Urea, N-[4-(3-amino-4-bromo-1H-indazol-6-yl)phenyl]-N'-(3-methylphenyl)- (CA INDEX NAME)




L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
2003:931339 Document No. 140:50440 Preparation of 3-aminoindazole derivatives as kinase inhibitors. Martina, Katia; Brill, Wolfgang (Pharmacia Italia S.P.A., Italy). PCT Int. Appl. WO 2003097610 A1 20031127, 99 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.
APPLICATION: WO 2003-EP4862 20030508. PRIORITY: US 2002-381092P 20020517.
GI




AB The title compds. [I; R = halo, (un)substituted alkenyl, alkynyl, (hetero)aryl (attached to position 5 or 6 of the indazole ring); R1 = N:CHNR2R3, NHCOR4, NHCONR4R5, NHSO2R4, NHCOR4; R2, R3 = H, alkyl; R4, R5 = H, alkyl, cycloalkyl, aryl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compds. comprising them, as well as combinatorial libraries of compds. I, are disclosed. Preparation of compds. I is described in nine synthetic examples. Thus, treating the resin bearing 6-(4-methoxyphenyl)-1H-indazol-3-amine (preparation given) with iso-Pr isocyanate followed by treatment with aqueous NH4OH, and cleavage from the resin afforded N-isopropyl-N'-[6-(4-methoxyphenyl)-1H-indazol-3-yl]urea. The compds. I or compns. may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.
IT 627848-14-0P 627848-15-1P 627848-16-2P
627848-91-3P 627848-92-4P 627848-93-5P
627849-36-9P 627849-37-0P 627858-25-7P
627858-26-8P 627858-27-9P 627858-28-0P
627858-29-1P 627858-30-4P 627858-31-5P
627858-32-6P 627858-33-7P 627858-34-8P
627859-06-7P 627859-07-8P 627859-08-9P
627859-09-0P 627859-10-3P 627859-11-4P
627859-12-5P 627859-13-6P 627859-14-7P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);


L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of 3-aminoindazole derivs. as kinase inhibitors)
RN 627848-14-0 CAPLUS
CN Cyclopentanepropanamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627848-15-1 CAPLUS
CN Butanamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]- (CA INDEX NAME)



RN 627848-16-2 CAPLUS
CN Propanamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-2-phenoxy- (CA INDEX NAME)




RN 627848-91-3 CAPLUS
CN Benzeneacetamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-3-methoxy- (CA INDEX NAME)




RN 627848-92-4 CAPLUS
CN Benzeneacetamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-α-phenyl- (CA INDEX NAME)


L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 627848-93-5 CAPLUS
CN Benzamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-3,4,5-trimethoxy- (CA INDEX NAME)



RN 627849-36-9 CAPLUS
CN Acetamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-2-(4-chlorophenoxy)- (CA INDEX NAME)




RN 627849-37-0 CAPLUS
CN Benzenepropanamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-α-[[4-(4-methylphenyl)sulfonyl]amino]- (CA INDEX NAME)




RN 627858-25-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]- (CA INDEX NAME)

10587989.trn


L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 627858-26-8 CAPLUS
CN Acetamide, N-[3-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)



RN 627858-27-9 CAPLUS
CN Acetamide, N-[3-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627858-28-0 CAPLUS
CN Acetamide, N-[3-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627858-29-1 CAPLUS
CN Acetamide, N-[3-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)


L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 627858-34-8 CAPLUS
CN Acetamide, N-[3-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627859-06-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-4-methyl- (CA INDEX NAME)




RN 627859-07-8 CAPLUS
CN Acetamide, N-[3-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627859-08-9 CAPLUS
CN Acetamide, N-[3-[[[3-(2-aminopropyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 627858-30-4 CAPLUS
CN Acetamide, N-[3-[[[3-(2-phenylethyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)



RN 627858-31-5 CAPLUS
CN Acetamide, N-[3-[[[3-(3-phenylpropyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627858-32-6 CAPLUS
CN Acetamide, N-[3-[[[3-(3-phenylpropyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627858-33-7 CAPLUS
CN Acetamide, N-[3-[[[3-(3-phenylpropyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)

L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 627859-09-0 CAPLUS
CN Acetamide, N-[3-[[[3-(2-aminoethyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627859-10-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-4-hydroxy- (CA INDEX NAME)



RN 627859-11-4 CAPLUS
CN Acetamide, N-[3-[[[3-(3-hydroxypropyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627859-12-5 CAPLUS
CN Acetamide, N-[3-[[[3-(2-pyridinyl)ethyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




RN 627859-13-6 CAPLUS
CN Acetamide, N-[3-[[[3-(2-piperidinyl)ethyl]amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)

10587989.trn

L22 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 627859-14-7 CAPLUS
CN Acetamide, N-[3-[[[2-(acetethylamino)ethylamino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)




IT 627859-44-3P 627859-45-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-aminoindazole derivs. as kinase inhibitors)

RN 627859-44-3 CAPLUS
CN Acetamide, N-[3-[[[2-(methoxyphenyl)amino]carbonyl]amino]-1H-indazol-6-yl]phenyl]- (CA INDEX NAME)



RN 627859-45-4 CAPLUS
CN Glycine, N-[[[6-[3-(acetethylamino)phenyl]-1H-indazol-3-yl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)



10587989.trn

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

L15 61 S L6
L16 6 S L15 AND P38
L17 5 S L16 NOT L8
L18 1 S L16 AND L8
L19 36 S L15 AND KINASE
L20 4 S L19 AND PD<=2004
L21 13 S L19 AND PRD<=2004
L22 8 S L21 NOT L16

=> select

ENTER ANSWER SET OR SMARTSELECT L# OR (L22):122

ENTER ANSWER NUMBER OR RANGE (1-):1-

ENTER DISPLAY CODE (TI) OR ?:au

E1 THROUGH E45 ASSIGNED

=> file cpalus

'CPALUS' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'CAPLUS'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> s E1-E45

45 "DAI, YUJIA"/AU
118 "DAVIDSEN, STEVEN K."/AU

20 "ERICSSON, ANNA M."/AU
 14 "HARTANDI, KRESNA"/AU
 87 "JI, ZHIQIN"/AU
 89 "MICHAELIDES, MICHAEL R."/AU
 7 "ANAND, NEEL KUMAR"/AU
 141 "BEIER, NORBERT"/AU
 11 "BLAZEY, CHARLES M."/AU
 56 "BOUCHARD, HERVE"/AU
 5 "BOWLES, OWEN JOSEPH"/AU
 9 "BRILL, WOLFGANG"/AU
 15 "BURGDORF, LARS THORE"/AU
 14 "BUSSENIUS, JOERG"/AU
 16 "COSTANZO, SIMONA"/AU
 5 "CURTIS, JEFFRY KIMO"/AU
 14 "DESMAZEAU, PASCAL"/AU
 207 "DORSCH, DIETER"/AU
 1 "DREWRY, DAVID KENDALL"/AU
 7 "DUBENKO, LARISA"/AU
 63 "EDWARDS, CHRISTINE"/AU
 10 "GAUZY, LAURENCE"/AU
 91 "GERICKE, ROLF"/AU
 7 "HALLEY, FRANCK"/AU
 8 "HUNTER, ROBERT NEIL, III"/AU
 17 "JUNG, DAVID KENDALL"/AU
 19 "KENNEDY, ABIGAIL R."/AU
 24 "KERNS, JEFFREY, K."/AU
 45 "KHOURY, RICHARD G."/AU
 7 "KIM, ANGIE I."/AU
 686 "LANG, FLORIAN"/AU
 13 "LE BRUN, ALAIN"/AU
 86 "LEE, DENNIS"/AU
 9 "LINN, JAMES ANDREW"/AU
 2 "MANALO, JEAN-CLAIRE L."/AU
 25 "MARTINA, KATIA"/AU
 121 "MEDERSKI, WERNER"/AU
 9 "PETO, CSABA J."/AU
 19 "RICE, KENNETH D."/AU
 8 "SEHON, CLARK"/AU
 9 "SOUAILLE, CATHERINE"/AU
 34 "STAVENGER, ROBERT A."/AU
 42 "TABART, MICHEL"/AU
 17 "TSANG, TSZE H."/AU
 27 "VIVIANI, FABRICE"/AU
 L23 1815 ("DAI, YUJIA"/AU OR "DAVIDSEN, STEVEN K."/AU OR "ERICSSON, ANNA
 M."/AU OR "HARTANDI, KRESNA"/AU OR "JI, ZHIQIN"/AU OR "MICHAELID
 ES, MICHAEL R."/AU OR "ANAND, NEEL KUMAR"/AU OR "BEIER, NORBERT"
 /AU OR "BLAZEY, CHARLES M."/AU OR "BOUCHARD, HERVE"/AU OR "BOWLE
 S, OWEN JOSEPH"/AU OR "BRILL, WOLFGANG"/AU OR "BURGDORF, LARS
 THORE"/AU OR "BUSSENIUS, JOERG"/AU OR "COSTANZO, SIMONA"/AU OR
 "CURTIS, JEFFRY KIMO"/AU OR "DESMAZEAU, PASCAL"/AU OR "DORSCH,
 DIETER"/AU OR "DREWRY, DAVID KENDALL"/AU OR "DUBENKO, LARISA"/AU
 OR "EDWARDS, CHRISTINE"/AU OR "GAUZY, LAURENCE"/AU OR "GERICKE,
 ROLF"/AU OR "HALLEY, FRANCK"/AU OR "HUNTER, ROBERT NEIL, III"/A
 U OR "JUNG, DAVID KENDALL"/AU OR "KENNEDY, ABIGAIL R."/AU OR
 "KERNS, JEFFREY, K."/AU OR "KHOURY, RICHARD G."/AU OR "KIM, ANGI

10587989.trn

E I. "/AU OR "LANG, FLORIAN"/AU OR "LE BRUN, ALAIN"/AU OR "LEE,
DENNIS"/AU OR "LINN, JAMES ANDREW"/AU OR "MANALO, JEAN-CLAIRE
L. "/AU OR "MARTINA, KATIA"/AU OR "MEDERSKI, WERNER"/AU OR "PETO,
CSABA J. "/AU OR "RICE, KENNETH D. "/AU

=> s l23 and journal/dt
22672288 JOURNAL/DT
L24 1000 L23 AND JOURNAL/DT

=> s l24 and kinase
379490 KINASE
69447 KINASES
391032 KINASE
(KINASE OR KINASES)
L25 236 L24 AND KINASE

=> d scan ti

10587989.trn

L25 236 ANSWERS CAPLUS COPYRIGHT 2010 ACS on STN
TI Regulation of erythrocyte survival by AMP-activated protein kinase
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10587989.trn

=> analyze 125

ENTER ANSWER NUMBER OR RANGE (1-):1-

ENTER DISPLAY CODE (TI) OR ?:?

Enter one or more codes from the following list.

AB ----- Abstract Text
AC ----- Patent Application Country
AD ----- Patent Application Date
AI ----- Patent Application Information
AN ----- Accession Number
AP ----- Patent Application Number
APPS ---- Patent Application and Priority Number
AU ----- Author or Patent Inventor
AY ----- Patent Application Year
CC ----- CA Classification Codes
CS ----- Corporate Source or Patent Assignee
CS.DIV -- Corporate Source, Division
CS.ORG -- Corporate Source, Organization Name
CT ----- Controlled Term
CYA ----- Country Name of Author
DS ----- Designated States (Patents)
DT ----- Document Type
FAN ----- Family Accession Number
FS ----- File Segment
GENBANK - GENBANK Number
IC ----- International Patent Classification (IPC)
ICA ----- Additional (Supplementary) IPC
ICI ----- Index (Complementary) IPC
ICM ----- Main IPC
ICS ----- Secondary IPC
IN ----- Inventor Name
ISN ----- International Standard (Document) Number
ISSN----- ISSN
IPC ----- International Patent Classifications
IT ----- Index Entries
JT ----- Journal Title
LA ----- Language
NCL----- National Patent Classification Code
OS ----- Other Source
PA ----- Patent Assignee
PATS----- Patent Numbers
PC ----- Patent Country
PCS ----- Patent Countries
PD ----- Publication Date
PI ----- Patent Information
PK ----- Kind of Patent
PN ----- Patent Number
PRAI ---- Patent Priority Information
PRC ----- Patent Priority Country
PRD ----- Patent Priority Date
PRN ----- Patent Priority Number
PRY ----- Patent Priority Year
PY ----- Publication Year of Original Document
RE ----- Reference
REC ----- Reference Count
RAN.CA -- Reference CA File Accession Number

10587989.trn

RAN.CAPLUS --- Reference CAPLus File Accession Nummber
RAN.MEDLINE -- Reference MEDLINE File Accession Number
RAN.ALL ----- Reference Accession Numbers for All Files
RIN ----- Reference Inventor
RAU ----- Reference Author
RWK ----- Reference Work
RPG ----- Reference Page Number
RPN ----- Reference Patent Number
RPY ----- Reference Publication Year
RVL ----- Reference Publication Volume
RL ----- Roles
RN ----- CAS Registry Number
SO ----- Source
ST ----- Supplementary Terms (CA Keywords)
SX ----- Chemical Abstract Section Cross-Reference Code
TI ----- Title of Document
ENTER DISPLAY CODE (TI) OR ?:cc
L26 ANALYZE L25 1- CC : 55 TERMS

=> d 126
L26 ANALYZE L25 1- CC : 55 TERMS

TERM #	# OCC	# DOC	% DOC	CC
1	37	37	15.68	13-2
2	20	20	8.47	13-6
3	20	20	8.47	2-4
4	17	17	7.20	1-3
5	10	10	4.24	1-6
6	10	10	4.24	15-10
7	8	8	3.39	2-8
8	7	7	2.97	13-0
9	7	7	2.97	14-12
10	5	5	2.12	1-0
11	5	5	2.12	1
12	5	5	2.12	15-2

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 15:31:44 ON 04 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 30, 2010 (20100430/UP).

=> file caplus
FILE 'CAPLUS' ENTERED AT 15:38:15 ON 04 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

10587989.trn

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 May 2010 VOL 152 ISS 19
FILE LAST UPDATED: 3 May 2010 (20100503/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l16 and l8
L27 1 L16 AND L8

=> s l16 or l8
L28 12 L16 OR L8

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS

10587989.trn

L14 ANALYZE L11 1- ED : 4 TERMS

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

L15 61 S L6
L16 6 S L15 AND P38
L17 5 S L16 NOT L8
L18 1 S L16 AND L8
L19 36 S L15 AND KINASE
L20 4 S L19 AND PD<=2004
L21 13 S L19 AND PRD<=2004
L22 8 S L21 NOT L16
 SELECT L22 1- AU
L23 1815 S E1-E45
L24 1000 S L23 AND JOURNAL/DT
L25 236 S L24 AND KINASE
L26 ANALYZE L25 1- CC : 55 TERMS

FILE 'STNGUIDE' ENTERED AT 15:31:44 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:38:15 ON 04 MAY 2010

L27 1 S L16 AND L8
L28 12 S L16 OR L8

=> select l28
ENTER ANSWER NUMBER OR RANGE (1-):1-
ENTER DISPLAY CODE (TI) OR :?:
Enter one or more codes from the following list.
AB ----- Abstract Text
AC ----- Patent Application Country
AD ----- Patent Application Date
AI ----- Patent Application Information
AN ----- Accession Number
AP ----- Patent Application Number
APPS ----- Patent Application and Priority Number
AU ----- Author or Patent Inventor
AY ----- Patent Application Year
CC ----- CA Classification Codes
CS ----- Corporate Source or Patent Assignee
CS.DIV -- Corporate Source, Division
CS.ORG -- Corporate Source, Organization Name
CT ----- Controlled Term
CYA ----- Country Name of Author
DS ----- Designated States (Patents)
DT ----- Document Type
FAN ----- Family Accession Number
FS ----- File Segment
GENBANK - GENBANK Number
IC ----- International Patent Classification (IPC)
ICA ----- Additional (Supplementary) IPC
ICI ----- Index (Complementary) IPC
ICM ----- Main IPC
ICS ----- Secondary IPC
IN ----- Inventor Name
ISN ----- International Standard (Document) Number
ISSN----- ISSN

10587989.trn

IPC ----- International Patent Classifications
IT ----- Index Entries
JT ----- Journal Title
LA ----- Language
NCL----- National Patent Classification Code
OS ----- Other Source
PA ----- Patent Assignee
PATS----- Patent Numbers
PC ----- Patent Country
PCS ----- Patent Countries
PD ----- Publication Date
PI ----- Patent Information
PK ----- Kind of Patent
PN ----- Patent Number
PRAI ----- Patent Priority Information
PRC ----- Patent Priority Country
PRD ----- Patent Priority Date
PRN ----- Patent Priority Number
PRY ----- Patent Priority Year
PY ----- Publication Year of Original Document
RE ----- Reference
REC ----- Reference Count
RAN.CA -- Reference CA File Accession Number
RAN.CAPLUS --- Reference CAPLus File Accession Nummber
RAN.MEDLINE -- Reference MEDLINE File Accession Number
RAN.ALL ----- Reference Accession Numbers for All Files
RIN ----- Reference Inventor
RAU ----- Reference Author
RWK ----- Reference Work
RPG ----- Reference Page Number
RPN ----- Reference Patent Number
RPY ----- Reference Publication Year
RVL ----- Reference Publication Volume
RL ----- Roles
RN ----- CAS Registry Number
SO ----- Source
ST ----- Supplementary Terms (CA Keywords)
SX ----- Chemical Abstract Section Cross-Reference Code
TI ----- Title of Document
ENTER DISPLAY CODE (TI) OR ?:cs
E46 THROUGH E52 ASSIGNED

=> d

10587989.trn

L28 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2009:1618457 CAPLUS
DN 152:97493
TI Preparation of heterocyclylbenzamides, indanylbenzamides, and
indanylpyridinecarboxamides as G protein-coupled receptor GPR52 agonists
IN Setoh, Masaki; Miyahana, Yuhei; Kouno, Mitsunori
PA Takeda Pharmaceutical Company Limited, Japan
SO PCT Int. Appl., 252pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2009157196 A1 20091230 WO 2009-JP2902 20090624
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI JP 2008-166467 A 20080625
CS MARPAT 152:97493
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10587989.trn

=> d e46-e52
'E46-E52' IS NOT A VALID ACCESSION NUMBER

The number entered is not a valid accession number in this file.
Enter "HELP ACCESSION" at an arrow prompt (=>) for a list of valid
accession number formats in the current file.

=> analyze l28
ENTER ANSWER NUMBER OR RANGE (1-):1-
ENTER DISPLAY CODE (TI) OR ?:PA
L29 ANALYZE L28 1- PA : 5 TERMS

=> d l29
L29 ANALYZE L28 1- PA : 5 TERMS

TERM #	# OCC	# DOC	% DOC PA
1	5	5	41.67
2	1	1	8.33
3	1	1	8.33
4	1	1	8.33
5	1	1	8.33

***** END OF L29***

SMITHKLINE BEECHAM CORPORATION USA
AVENTIS PHARMA SA FR
BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM USA
EMORY UNIVERSITY USA
TAKEDA PHARMACEUTICAL COMPANY LIMITED JAPAN

=> s l28 and SMITHKLINE BEECHAM CORPORATION USA/pa
4810 SMITHKLINE/PA
5755 BEECHAM/PA
251622 CORPORATION/PA
913706 USA/PA
1865 SMITHKLINE BEECHAM CORPORATION USA/PA
((SMITHKLINE(S)BEECHAM(S)CORPORATION(S)USA)/PA)
L30 5 L28 AND SMITHKLINE BEECHAM CORPORATION USA/PA

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

10587989.trn

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

L15 61 S L6
L16 6 S L15 AND P38
L17 5 S L16 NOT L8
L18 1 S L16 AND L8
L19 36 S L15 AND KINASE
L20 4 S L19 AND PD<=2004
L21 13 S L19 AND PRD<=2004
L22 8 S L21 NOT L16
SELECT L22 1- AU
L23 1815 S E1-E45
L24 1000 S L23 AND JOURNAL/DT
L25 236 S L24 AND KINASE
L26 ANALYZE L25 1- CC : 55 TERMS

FILE 'STNGUIDE' ENTERED AT 15:31:44 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:38:15 ON 04 MAY 2010

L27 1 S L16 AND L8
L28 12 S L16 OR L8
SELECT L28 1- CS
L29 ANALYZE L28 1- PA : 5 TERMS
L30 5 S L28 AND SMITHKLINE BEECHAM CORPORATION USA/PA

=> select 130
ENTER ANSWER NUMBER OR RANGE (1-):1-
ENTER DISPLAY CODE (TI) OR ?:au
E53 THROUGH E64 ASSIGNED

=> file uspatfull
FILE 'USPATFULL' ENTERED AT 15:41:14 ON 04 MAY 2010
CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 4 May 2010 (20100504/PD)
FILE LAST UPDATED: 4 May 2010 (20100504/ED)
HIGHEST GRANTED PATENT NUMBER: US7712147
HIGHEST APPLICATION PUBLICATION NUMBER: US20100107290
CA INDEXING IS CURRENT THROUGH 4 May 2010 (20100504/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 4 May 2010 (20100504/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

To ensure comprehensive retrieval of US patent information, including US patent application information, search USPATFULL in combination with USPAT2.

10587989.trn

=> s E53-E64

```

    17 "SWANSON, STEPHEN"/AU
    14 "PATEL, VIPULKUMAR KANTIBHAI"/AU
    27 "WALKER, ANN LOUISE"/AU
    27 "BAMBOROUGH, PAUL"/AU
    5 "CAMPOS, SEBASTIEN ANDRE"/AU
    16 "ANGELL, RICHARD MARTYN"/AU
    5 "BALDWIN, IAN ROBERT"/AU
    11 "BARKER, MICHAEL DAVID"/AU
    1 "DEBOECK, NIGEL MARC"/AU
    16 "HAMBLIN, JULIE NICOLE"/AU
    2 "JONES, KATHERINE LOUISE"/AU
    3 "LONGSTAFF, TIMOTHY"/AU
L31  74 ("SWANSON, STEPHEN"/AU OR "PATEL, VIPULKUMAR KANTIBHAI"/AU OR
      "WALKER, ANN LOUISE"/AU OR "BAMBOROUGH, PAUL"/AU OR "CAMPOS,
      SEBASTIEN ANDRE"/AU OR "ANGELL, RICHARD MARTYN"/AU OR "BALDWIN,
      IAN ROBERT"/AU OR "BARKER, MICHAEL DAVID"/AU OR "DEBOECK, NIGEL
      MARC"/AU OR "HAMBLIN, JULIE NICOLE"/AU OR "JONES, KATHERINE LOUI
      SE"/AU OR "LONGSTAFF, TIMOTHY"/AU)
```

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

```

L1      STRUCTURE UPLOADED
L2      STRUCTURE UPLOADED
L3      36 S L1
L4      11 S L2
L5      33 S L1 OR L2
L6      1663 S L1 OR L2 FULL
L7      125 S L6 AND C6N3/RF
```

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

```

L10     845 SEA L9
L11     5 S L7 NOT L10
L12     ANALYZE L11 1- SR :      4 TERMS
L13     ANALYZE L12 1- :      4 TERMS
L14     ANALYZE L11 1- ED :      4 TERMS
```

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

```

L15     61 S L6
L16     6 S L15 AND P38
L17     5 S L16 NOT L8
L18     1 S L16 AND L8
L19     36 S L15 AND KINASE
```

10587989.trn

```
L20          4 S L19 AND PD<=2004
L21          13 S L19 AND PRD<=2004
L22          8 S L21 NOT L16
              SELECT L22 1- AU
L23          1815 S E1-E45
L24          1000 S L23 AND JOURNAL/DT
L25          236 S L24 AND KINASE
L26          ANALYZE L25 1- CC :      55 TERMS
```

FILE 'STNGUIDE' ENTERED AT 15:31:44 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:38:15 ON 04 MAY 2010

```
L27          1 S L16 AND L8
L28          12 S L16 OR L8
              SELECT L28 1- CS
L29          ANALYZE L28 1- PA :      5 TERMS
L30          5 S L28 AND SMITHKLINE BEECHAM CORPORATION USA/PA
              SELECT L30 1- AU
```

FILE 'USPATFULL' ENTERED AT 15:41:14 ON 04 MAY 2010

```
L31          74 S E53-E64

=> s l31 and kinase
          95377 KINASE
          34325 KINASES
          100295 KINASE
              (KINASE OR KINASES)
L32          36 L31 AND KINASE
```

```
=> s l32 and p38
          7649 P38
L33          25 L32 AND P38
```

```
=> d cbib abs 1-
YOU HAVE REQUESTED DATA FROM 25 ANSWERS - CONTINUE? Y/(N):y
```


10587989.trn

L33 ANSWER 1 OF 25 USPATFULL on STN
2009:173981 Novel Compounds.
Callahan, James F., King of Prussia, PA, UNITED STATES
Boehm, Jeffrey C., King of Prussia, PA, UNITED STATES
Cooper, Anthony William James, Stevenage, UNITED KINGDOM
Livia, Stefano, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Nevins, Neysa, King of Prussia, PA, UNITED STATES
Wan, Zehong, King of Prussia, PA, UNITED STATES
Norton, Beth A., Research Triangle Park, NC, UNITED STATES
Lin, Xichen, King of Prussia, PA, UNITED STATES
Glaxo Group Limited (U.S. corporation)
US 20090156597 A1 20090618
APPLICATION: US 2008-132793 A1 20080604 (12)
PRIORITY: US 2005-665315P 20050325 (60)
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one
containing compounds and compositions, and their use in therapy as
CSBP/RK/p38 kinase inhibitors.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 2 OF 25 USPATFULL on STN
2009:25645 Fused Heteroaryl Derivatives for Use as P38 Kinase
Inhibitors.
Bamborough, Paul, Hertfordshire, UNITED KINGDOM
Campos, Sebastien Andre, Hertfordshire, UNITED KINGDOM
Patel, Vipulkumar Kantibhai, Hertfordshire, UNITED KINGDOM
Swanson, Stephen, Hertfordshire, UNITED KINGDOM
Walker, Ann Louise, Hertfordshire, UNITED KINGDOM
US 20090023725 A1 20090122
APPLICATION: US 2005-587790 A1 20050127 (10)
WO 2005-GB265 20050127 20060728 PCT 371 date
PRIORITY: GB 2004-2143 20040130
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I):

##STR1##

are inhibitors of p38 kinase and are useful in the
treatment of conditions or disease states mediated by p38
kinase activity or mediated by cytokines produced by the
activity of p38.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 3 OF 25 USPATFULL on STN
2008:246655 N-(2,2-Dimethylpropyl)-6- -3-Pyridinecarboxamide.
Chandi, Amrik, Hertfordshire, UNITED KINGDOM
Keel, Trevor Raymond, Hertfordshire, UNITED KINGDOM
Patel, Vipulkumar Kantibhai, Hertfordshire, UNITED KINGDOM
Walker, Ann Louise, Hertfordshire, UNITED KINGDOM
US 20080214623 A1 20080904
APPLICATION: US 2006-917534 A1 20060616 (11)
WO 2006-GB2212 20060616 20071214 PCT 371 date
PRIORITY: GB 2005-12429 20050617
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel compound, processes for its
preparation, compositions comprising the same and its use in the
treatment of condition or diseases mediated by p38
kinase activity.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 4 OF 25 USPATFULL on STN
2008:5117 NOVEL COMPOUNDS.
Gore, Paul Martin, Stevenage, UNITED KINGDOM
Patel, Vipulkumar Kantibhai, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20080004295 A1 20080103
APPLICATION: US 2006-548343 A1 20061011 (11)
PRIORITY: GB 2005-20838 20051013
GB 2006-13485 20060706
GB 2006-18237 20060915
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pyrrolopyrimidine derivatives of formula (I) are inhibitors of Spleen
Tyrosine Kinase (Syk) and therefore of potential therapeutic
benefit in the treatment of diseases and conditions associated with
inappropriate Syk activity, in particular in the treatment of
inflammatory and allergic diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10587989.trn

L33 ANSWER 5 OF 25 USPATFULL on STN
2007:184691 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as
p38 kinase inhibitors.
Walker, Ann Louise, Hertfordshire, UNITED KINGDOM
SIMITHKLINE BEECHMAN CORPORATION, Philadelphia, PA, UNITED STATES (U.S.
corporation)
US 20070161684 A1 20070712
APPLICATION: US 2004-568121 A1 20040809 (10)
WO 2004-EF8972 20040809 20061201 PCT 371 date
PRIORITY: GB 2003-18814 20030811
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## or pharmaceutically acceptable
derivatives thereof, and their use as pharmaceuticals, particularly as
p38 kinase inhibitors.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 6 OF 25 USPATFULL on STN
2007:184680 P38 kinase inhibitors.
Barker, Michael David, Hertfordshire, UNITED KINGDOM
Hamblin, Julie Nicole, Hertfordshire, UNITED KINGDOM
Jones, Katherine Louise, Hertfordshire, UNITED KINGDOM
Patel, Vipulkumar Kantibhai, Hertfordshire, UNITED KINGDOM
Swanson, Stephen, Hertfordshire, UNITED KINGDOM
Walker, Ann Louise, Hertfordshire, UNITED KINGDOM
US 20070161673 A1 20070712
APPLICATION: US 2005-587989 A1 20050127 (10)
WO 2005-GB274 20050127 20060728 PCT 371 date
PRIORITY: GB 2004-2137 20040130
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## are inhibitors of p38
kinase and are useful in the treatment of conditions or disease
states mediated by p38 kinase activity or mediated
by cytokines produced by the activity of p38.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 7 OF 25 USPATFULL on STN
2007:162919 Biphenyl-Derivatives as p38 Kinase Inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Banford, Mark James, Harlow, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Flack, Stephen Sean, London, UNITED KINGDOM
Laine, Dramane Ibrahim, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
Glaxo Group Limited (non-U.S. corporation)
US 20070142476 A1 20070621
APPLICATION: US 2007-669219 A1 20070131 (11)
PRIORITY: GB 2001-24934 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## or pharmaceutically acceptable
salts or solvates thereof, and their use as pharmaceuticals,
particularly as p38 kinase inhibitors.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 8 OF 25 USPATFULL on STN
2007:162816 Fused heteroaryl derivatives for use as p38
kinase inhibitors in the treatment of i.a. rheumatoid arthritis.
Campos, Sebastien Andre, Hertfordshire, UNITED KINGDOM
Swanson, Stephen, Hertfordshire, UNITED KINGDOM
Walker, Ann Louise, Hertfordshire, UNITED KINGDOM
US 20070142372 A1 20070621
APPLICATION: US 2005-587614 A1 20050127 (10)
WO 2005-GB281 20050127 20060728 PCT 371 date
PRIORITY: GB 2004-2140 20040130
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## are inhibitors of p38
kinase and are useful in the treatment of conditions or disease
states mediated by p38 kinase activity or mediated
by cytokines produced by the activity of p38.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10587989.trn

L33 ANSWER 9 OF 25 USPATFULL on STN
2007:148257 Biphenyl carboxylic amide p38 kinase inhibitors
Aston, Nicola Mary, Hertfordshire, UNITED KINGDOM
Bamborough, Paul, Hertfordshire, UNITED KINGDOM
Jones, Katherine Louise, Hertfordshire, UNITED KINGDOM
Patel, Vipulkumar Kantibhai, Hertfordshire, UNITED KINGDOM
Swanson, Stephen, Hertfordshire, UNITED KINGDOM
Walker, Ann Louise, Hertfordshire, UNITED KINGDOM
US 20070129354 A1 20070607
APPLICATION: US 2004-551502 A1 20040407 (10)
WO 2004-EP3774 20040407 20060628 PCT 371 date
PRIORITY: GB 2003-8186 20030909
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compound of formula (I): ##STR1## or pharmaceutically acceptable
derivatives thereof, and their use as pharmaceuticals, particularly as
p38 kinase inhibitors.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 10 OF 25 USPATFULL on STN
2007:128690 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide
Derivatives and Their Use As P38 Kinase Inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Smith, Kathryn Jane, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
Glaxo Group Limited (non-U.S. corporation)
US 20070112046 A1 20070517
APPLICATION: US 2006-557607 A1 20061108 (11)
PRIORITY: GB 2001-24938 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## or pharmaceutically acceptable
salts or solvates thereof, and their use as pharmaceuticals,
particularly as p38 kinase inhibitors.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 11 OF 25 USPATFULL on STN
2007:121654 Biphenylcarboxylic Amide Derivatives as p38
Kinase Inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Bamford, Mark James, Harlow, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Flack, Stephen Sean, London, UNITED KINGDOM
Laine, Dramane Ibrahim, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
Glaxo Group Limited (non-U.S. corporation)
US 20070105860 A1 20070510
APPLICATION: US 2006-556285 A1 20061103 (11)
PRIORITY: GB 2001-24933 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## or pharmaceutically acceptable
salts or solvates thereof, and their use as pharmaceuticals,
particularly as p38 kinase inhibitors.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 12 OF 25 USPATFULL on STN
2007:62797 Fused heteroaryl derivatives and their use as p38
kinase inhibitors.
Patel, Vipulkumar K., Hertfordshire, UNITED KINGDOM
Swanson, Stephen, Hertfordshire, UNITED KINGDOM
US 20070054942 A1 20070308
APPLICATION: US 2005-587613 A1 20050127 (10)
WO 2005-GB266 20050127 20060728 PCT 371 date
PRIORITY: GB 2004-2138 20040130
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## are inhibitors of p38
kinase and are useful in the treatment of conditions or disease
states mediated by p38 kinase activity or mediated
by cytokines produced by the activity of p38.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10587989.trn

L33 ANSWER 13 OF 25 USPATFULL on STN
2006:322470 Nicotinamide Derivatives Useful as p38 Inhibitors.
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
SmithKline Beecham Corporation (non-U.S. corporation)
US 20060276516 A1 20061207
APPLICATION: US 2006-462858 A1 20060807 (11)
PRIORITY: GB 2002-25385 20021031
GB 2002-3301 20020212
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## are inhibitors of p38
kinase and are useful in the treatment of conditions or disease
states mediated by p38 kinase activity or mediated
by cytokines produced by the activity of p38.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 14 OF 25 USPATFULL on STN
2006:308866 Nicotinamide Derivatives Useful as p38 Inhibitors.
Aston, Nicola, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Walker, Ann, Stevenage, UNITED KINGDOM
SmithKline Beecham Corporation (non-U.S. corporation)
US 20060264479 A1 20061123
APPLICATION: US 2006-462851 A1 20060807 (11)
PRIORITY: GB 2002-3301 20020212
GB 2002-25385 20021031
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## are inhibitors of p38
kinase and are useful in the treatment of conditions or disease
states mediated by p38 kinase activity or mediated
by cytokines produced by the activity of p38.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 15 OF 25 USPATFULL on STN
2006:144702 Fused heteroaryl derivatives for use as p38
kinase inhibitors in the treatment of i.a. rheumatoid arthritis.
Angell, Richard Martyn, London, UNITED KINGDOM
Baldwin, Ian Robert, Hertfordshire, UNITED KINGDOM
Bamborough, Paul, Hertfordshire, UNITED KINGDOM
Debeck, Nigel Marc, Hertfordshire, UNITED KINGDOM
Longstaff, Timothy, Hertfordshire, UNITED KINGDOM
Swanson, Stephen, Hertfordshire, UNITED KINGDOM
US 20060122221 A1 20060608
APPLICATION: US 2003-522955 A1 20030730 (10)
WO 2003-GB3316 20030730 20051114 PCT 371 date
PRIORITY: GB 2002-17757 20020731
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are
inhibitors of p38 kinase and are useful in the
treatment of conditions or disease states mediated by p38
kinase activity or mediated by cytokines produced by the
activity of p38, such as rheumatoid arthritis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 16 OF 25 USPATFULL on STN
2006:105285 Heteroaryl substituted biphenyl derivatives as p38
kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Baldwin, Ian Robert, Stevenage, UNITED KINGDOM
Li-Kwai-Cheung, Anne-Marie, Harlow, UNITED KINGDOM
Longstaff, Timothy, Stevenage, UNITED KINGDOM
Merrick, Suzanne Joy, Stevenage, UNITED KINGDOM
Smith, Kathryn Jane, Stevenage, UNITED KINGDOM
Swanson, Stephen, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20060089393 A1 20060427
APPLICATION: US 2003-513095 A1 20030429 (10)
WO 2003-GB1834 20030429 20050826 PCT 371 date
PRIORITY: GB 2002-9891 20020430
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) are inhibitors of p38 kinase
and are useful in the treatment of conditions or disease states
mediated
by p38 kinase activity or mediated by cytokines
produced by the activity of p38. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10587989.trn

L33 ANSWER 17 OF 25 USPATFULL on STN
2005:203538 Nicotinamide derivatives useful as p38 inhibitors.
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20050176964 A1 20050811
APPLICATION: US 2003-503968 A1 20030210 (10)
WO 2003-GB554 20030210
PRIORITY: GB 2002-3301 20020212
GB 2002-25385 20021031
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1## are inhibitors of p38
kinase and are useful in the treatment of conditions or disease
states mediated by p38 kinase activity or mediated
by cytokines produced by the activity of p38.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 18 OF 25 USPATFULL on STN
2005:105553 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide
derivatives and their use as p38 kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Smith, Kathryn Jane, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20050090491 A1 20050428
APPLICATION: US 2003-492497 A1 20021016 (10)
WO 2002-EP11575 20021016
PRIORITY: GB 2001-24938 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) wherein when m is 0 to 4 R1 is selected from
C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, --SO2NR4R5, --CONR4R5 and
--COOR4; and when m is 2 to 4 R1 is additionally selected from
C1-6alkoxy, hydroxy, NR4R5, --NR4SO2R5, --NR4SOR5, --NR4COR5, and
--NR4CONR4R5; R2 is selected from hydrogen, C1-6alkyl and
--(CH2)n--C3-7cycloalkyl; R3 is the group R6 is selected from hydrogen
and C1-4alkyl; U is selected from methyl and halogen; X and Y are each
selected independently from hydrogen, methyl and halogen; m is selected
from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon
chain may be optionally substituted with one or two groups selected
independently from C1-6alkyl; n is selected from 0, 1, 2 and 3; x is
selected from 0, 1 and 2; or pharmaceutically acceptable salts or
solvates thereof, and their use as pharmaceuticals, particularly as
p38 kinase inhibitors. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 19 OF 25 USPATFULL on STN
2005:75894 Oxadiazolyl-biphenylcarboxamides and their use as p38
kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Smith, Kathryn Jane, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20050065195 A1 20050324
APPLICATION: US 2004-492711 A1 20041029 (10)
WO 2002-EP11574 20021016
PRIORITY: GB 2001-249325 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ##STR1##

Compounds of formula (I), wherein R3 is the group; or pharmaceutically
acceptable salts or solvates thereof, and their use as pharmaceuticals,
particularly as p38 kinase inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 20 OF 25 USPATFULL on STN
2005:44281 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use
as p38 kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Bamford, Mark James, Harlow, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Merrick, Suzanne Joy, London, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20050038014 A1 20050217
APPLICATION: US 2004-492699 A1 20041012 (10)
WO 2002-EP11573 20021016
PRIORITY: GB 2001-24931 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1##

or pharmaceutically acceptable salts or solvates thereof, and their use
as pharmaceuticals, particularly as p38 kinase
inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10587989.trn

L33 ANSWER 21 OF 25 USPATFULL on STN
2005:23991 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Bamford, Mark James, Harlow, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Flack, Stephen Sean, London, UNITED KINGDOM
Laine, Dramane Ibrahim, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20050020540 A1 20050127
APPLICATION: US 2004-492697 A1 20040415 (10)
WO 2002-EP11572 20021016
PRIORITY: GB 2001-24933 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. ##STR1##
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 22 OF 25 USPATFULL on STN
2004:335917 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Merrick, Suzanne Joy, Stevenage, UNITED KINGDOM
Smith, Kathryn Jane, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20040267012 A1 20041230
APPLICATION: US 2004-492698 A1 20040415 (10)
WO 2002-EP11577 20021016
PRIORITY: GB 2001-24941 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): wherein when m is 0 to 4 R1 is selected from C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, --SO2NR4R5, --CONR4R5 and --COOR4; and when m is 2 to 4 R1 is additionally selected from C1-6alkoxy, hydroxy, NR4R5, --NR4SO2R5, --NR4SOR5, --NR4COR5, and --NR4CONR4R5; R2 is selected from hydrogen, C1-6alkyl and --(CH2)n-C3-7cycloalkyl; R3 is the group --CO--NH--(CH2)p-R6; U is selected from methyl and halogen; W is selected from methyl and chlorine; V and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1-6alkyl; n is selected from 0, 1, 2 and 3; p and r are independently selected from 0, 1 and 2; s is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. ##STR1##
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 23 OF 25 USPATFULL on STN
2004:335745 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20040266839 A1 20041230
APPLICATION: US 2004-492713 A1 20040415 (10)
WO 2002-EP11569 20021016
PRIORITY: GB 2001-24936 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I), wherein R.sup.1 is a phenyl group which may be optionally substituted; R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl and (CH.sub.2).sub.p--C.sub.3-7cycloalkyl; R.sup.3 is the group: (Formula II), R.sup.4 is selected from hydrogen and C.sub.1-4 alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C.sub.1-6 alkyl; n is selected from 0, 1 and 2; p is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. ##STR1##
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L33 ANSWER 24 OF 25 USPATFULL on STN
2004:315484 Biphenyl-derivatives as p38-kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Bamford, Mark James, Harlow, UNITED KINGDOM
Cockerill, George Stuart, London, UNITED KINGDOM
Flack, Stephen Sean, London, UNITED KINGDOM
Laine, Dramane Ibrahim, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20040249161 A1 20041209
APPLICATION: US 2004-492715 A1 20040415 (10)
WO 2002-EP11571 20021016
PRIORITY: GB 2001-24934 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. ##STR1##
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10587989.trn

L33 ANSWER 25 OF 25 USPATFULL on STN
2004:308192 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use
as p38 kinase inhibitors.
Angell, Richard Martyn, London, UNITED KINGDOM
Aston, Nicola Mary, Stevenage, UNITED KINGDOM
Bamborough, Paul, Stevenage, UNITED KINGDOM
Bamford, Mark James, Harlow, UNITED KINGDOM
Cockerhill, George Stuart, London, UNITED KINGDOM
Flack, Stephen Sean, London, UNITED KINGDOM
Laine, Dramane Ibrahim, Stevenage, UNITED KINGDOM
Merrick, Suzanne Joy, Stevenage, UNITED KINGDOM
Smith, Kathryn Jane, Stevenage, UNITED KINGDOM
Walker, Ann Louise, Stevenage, UNITED KINGDOM
US 20040242868 A1 20041202
APPLICATION: US 2004-492605 A1 20040415 (10)
WO 2002-EP11576 20021016
PRIORITY: GB 2001-24939 20011017
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1##

or pharmaceutically acceptable salts or solvates thereof, and their use
as pharmaceuticals, particularly as p38 kinase
inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10587989.trn

=> d his

(FILE 'HOME' ENTERED AT 15:17:32 ON 04 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:17:44 ON 04 MAY 2010

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 36 S L1
L4 11 S L2
L5 33 S L1 OR L2
L6 1663 S L1 OR L2 FULL
L7 125 S L6 AND C6N3/RF

FILE 'CAPLUS' ENTERED AT 15:21:44 ON 04 MAY 2010

L8 7 S L7

FILE 'REGISTRY' ENTERED AT 15:22:01 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:22:05 ON 04 MAY 2010

L9 TRA L8 1- RN : 845 TERMS

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 04 MAY 2010

L10 845 SEA L9
L11 5 S L7 NOT L10
L12 ANALYZE L11 1- SR : 4 TERMS
L13 ANALYZE L12 1- : 4 TERMS
L14 ANALYZE L11 1- ED : 4 TERMS

FILE 'CAPLUS' ENTERED AT 15:24:11 ON 04 MAY 2010

L15 61 S L6
L16 6 S L15 AND P38
L17 5 S L16 NOT L8
L18 1 S L16 AND L8
L19 36 S L15 AND KINASE
L20 4 S L19 AND PD<=2004
L21 13 S L19 AND PRD<=2004
L22 8 S L21 NOT L16
 SELECT L22 1- AU
L23 1815 S E1-E45
L24 1000 S L23 AND JOURNAL/DT
L25 236 S L24 AND KINASE
L26 ANALYZE L25 1- CC : 55 TERMS

FILE 'STNGUIDE' ENTERED AT 15:31:44 ON 04 MAY 2010

FILE 'CAPLUS' ENTERED AT 15:38:15 ON 04 MAY 2010

L27 1 S L16 AND L8
L28 12 S L16 OR L8
 SELECT L28 1- CS
L29 ANALYZE L28 1- PA : 5 TERMS
L30 5 S L28 AND SMITHKLINE BEECHAM CORPORATION USA/PA
 SELECT L30 1- AU

FILE 'USPATFULL' ENTERED AT 15:41:14 ON 04 MAY 2010

L31 74 S E53-E64

10587989.trn

L32 36 S L31 AND KINASE
L33 25 S L32 AND P38

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED AT 16:09:33 ON 04 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 30, 2010 (20100430/UP).